



Vaccines and Global Health: The Week in Review
22 May 2021 :: Issue 608
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 21,000 entries.***

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

- A. Milestones :: Perspectives :: Featured Journal Content
- B. Emergencies
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

Milestones :: Perspectives :: Research

Editor's Note:

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:

david.r.curry@ge2p2global.org

.....
.....

World Health Assembly

Seventy-fourth World Health Assembly #WHA74

24 May to 1 June 2021

Theme: Ending this pandemic, preventing the next: building together a healthier, safer and fairer world.

:: [Provisional agenda](#)

:: [Watch live WHA74 sessions](#)

:: [Documents](#)

World Health Assembly to focus on ending COVID-19 pandemic and preparing for next one

News release 19 May 2021

In a year when COVID-19 threatens the health and well-being of everyone on the planet, the seventy-fourth session of the World Health Assembly (WHA) will stress the urgency of ending the current pandemic and preventing the next one by building a healthier, safer and fairer world...

This year's World Health Assembly will play a vital role in shaping the global health architecture of the future, and in strengthening WHO to fulfil its mission and mandate", added Dr Tedros.

The Assembly's agenda will focus on the health-related Sustainable Development Goals and WHO's Triple Billion targets of one billion more people benefitting from universal health coverage; one billion more better protected from health emergencies; and one billion more enjoying better health and well-being...

.....
.....

Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 27 May 2021

27 May 2021

This extraordinary virtual meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will take place on Thursday 27 May 2021 to propose recommendations to WHO on the use of COVID-19 vaccine(s).

:: [Agenda](#)

.....

.....

COVID – Multilateral Action

[Global leaders adopt agenda to overcome COVID-19 crisis and avoid future pandemics](#)

Press release 21 May 2021

Leaders of the G20 committed today to a series of actions to accelerate the end of the COVID-19 crisis everywhere and better prepare for future pandemics, at a summit co-hosted by European Commission President Ursula von der Leyen and Italian Prime Minister Mario Draghi, as G20 chair.

President Ursula von der Leyen said: "This very first G20 summit on health marks the beginning of a new chapter in global health policy. **World leaders strongly committed to multilateralism and global cooperation in health. This means, no export bans, keeping global supply chains open and working to extend production capacity everywhere.** If we live up to these principles, the world will be better prepared for pandemics."

The G20 underlined the importance of increased and diversified manufacturing and **recognised the role of intellectual property in ensuring equity, both through voluntary licensing and knowledge transfer, as well as in the context of the flexibilities provided by the TRIPS agreement. In that respect, the EU intends to facilitate the implementation of those flexibilities, in particular the use of compulsory licenses including for exports to all countries that lack manufacturing capacity.***

The EU will come forward with a proposal in the WTO focusing on:

- :: clarifying and facilitating the use of compulsory licences in crisis times like this pandemic;
- :: supporting the expansion of production;
- :: trade facilitation and limiting export restrictions.

All G20 members also acknowledged the need to address the funding gap of the ACT-Accelerator, a global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines, and launched by the WHO, the European Commission, France and the Bill & Melinda Gates Foundation. **And agreed to extend its mandate to the end of 2022.**

The leaders further agreed on the need for early warning information, surveillance and trigger systems, which will be interoperable. These will cover new viruses, but also variants. They will enable countries to detect much quicker and to act to nip in the bud outbreaks, before they become pandemics.

G20 clearly stressed the need to ensure equitable access to vaccines and to support low and middle-income countries...

.....

.....

[G20 Scientific Expert Panel, Co-Chaired by NAM President, Identifies Key Recommendations to Address Global Health Crises](#)

May 21, 2021

Today, the Global Health Summit Scientific Expert Panel, established by the G20 and European Commission, co-chaired by NAM president Victor J. Dzau, presented key recommendations and characteristics of effective systems for health threat prevention, preparedness, and response at the Global Health Summit to G20 members, heads of international and regional organizations, and representatives of global health bodies.

The Panel's Report provided COVID-19-informed, evidence-based principles that aim to offer forward-looking structural changes to prepare and respond to future global health emergencies. Key areas of the Panel's report address global equitable access to supplies, research, and innovation; integrated disease surveillance and data-sharing; sustainable health; and more. To achieve these principles, the Panel emphasized the importance of sourcing and allocating appropriate funding to protect the world's collective health.

"In order to effectively address the current and future threats to our global health, we need scientifically-driven solutions, international cooperation, and structures and resources to ensure equitable access to vaccines, therapeutics, and other resources to combat pandemic diseases," said Dzau.

The Panel identified ten evidence-based areas in need of urgent action:

- :: End the acute stage of the pandemic and leave no one behind: Ensure equitable access to medical tools to fight COVID-19;
- :: Invest in scientific research & development before, during, and in between health crises;
- :: Actively and genuinely involve research groups in low- and middle-income countries;
- :: Strengthen integrated disease surveillance, data collection, analysis, and sharing at all levels;
- Strengthen and protect science advice;
- :: Be ready for the next health crisis: Invest in standing systems and workforce for preparedness and response;
- :: Strengthen regional manufacturing capacities and hubs;
- :: Empower and earn the trust of people;
- :: Collaborate & coordinate at all levels: Strengthen relevant governance structures and leadership, and ensure adequate financing; and
- :: Address the problem at the root: Reduce risks through more sustainable ways of living

Findings presented at the G20 Global Health Summit will help shape the creation of a "Rome Declaration:" a set of guiding principles for mid- to long-term structural change, which, along with joint global action, can address and prevent future global health crises.

The Panel, consisting of 27 eminent international scientists and experts, was co-chaired by Professor Peter Piot, Special adviser to the President of the European Commission Ursula von der Leyen; Professor Silvio Brusaferro, President of the Italian National Institute of Health; Professor Victor Dzau, President of the United States National Academy of Medicine; Professor Yee-Sin Leo, Director of the National Centre for Infectious Diseases in Singapore; Professor John Nkengasong, Director of the Africa Centers for Disease Control and Prevention. [The complete list of Panel members is available here.](#)

[Read the Panel's full report here.](#)

.....
.....

COVID Vaccines/Immunization – Equity/Access/Dose Sharing

Editor's Note:

We aggregate below a number of announcements and calls-to-action from the past week around equity/access/dose sharing.

Gavi - [Global leaders renew their commitment to address urgency of COVID-19 pandemic](#)

:: At today's Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC)

:: Italy committed EUR 300 million to the Gavi COVAX AMC, which will count towards COVAX's goal of procuring 1.8 billion COVID-19 vaccine doses for lower-income economies in 2021.

:: In addition, France, Germany, Italy, The Netherlands, Norway, Spain and Switzerland – as part of Team Europe – pledged to share a combined total of over 100 million vaccine doses with middle- and low-income economies, boosting short term supplies.

Geneva, 21 May 2021 – The Global Health Summit, hosted by the European Commission and Italy as chair of the G20, saw governments announce support to the Gavi COVAX Advance Market Commitment (AMC), including a pledge of EUR 300 million from Italy. **The commitment brings the total amount of funds raised for the Gavi COVAX AMC, the funding mechanism to finance doses of COVID-19 vaccines for 92 lower-income economies within the COVAX Facility, to over US\$ 7 billion.**

In addition, Team Europe announced the largest dose sharing donation to date, with 100 million doses of COVID-19 vaccines going to lower-income economies with a majority of them through the COVAX AMC. Donors include France and Germany who stated they would be sharing 30 million surplus doses each and Italy who will be donating 15 million doses by the end of 2021.

This additional funding comes at a time when COVAX is looking to secure a total of US\$8.3 billion from sovereign donors and the private sector for 2020-21 in order to accelerate access to 1.8 billion COVID-19 vaccine doses for lower-income economies. In addition, to support AMC eligible economies' that want to buy additional doses through COVAX, a further US\$1 billion is being sought from multilateral development banks to support a cost-sharing initiative.

The campaign will culminate at the virtual Gavi COVAX Advance Market Commitment (AMC) Summit – One World Protected – Committed to Deliver on the 2nd June, which will be co-hosted by Japanese Prime Minister H.E. Yoshihide Suga together with José Manuel Barroso, Chair of the Gavi Board.

"COVAX has built the systems to deliver vaccines to low and lower middle income countries; we welcome the support of the G-20 countries to help us scale up volumes and reduce vaccine inequities. Today's funding, especially the very generous commitment from Italy and dose donation pledges demonstrate that global leadership understands that it's time to unleash COVAX's full potential to bring the acute phase of this pandemic to an end," said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. **"Funding the AMC and sharing doses with COVAX are among the most effective interventions a country can make to control COVID-19 and we urge all governments to work with us in protecting people everywhere."**

Securing 1.8 billion doses would enable the Gavi COVAX AMC to protect nearly 30% of the population in 92 lower-income countries, or roughly half the adult population. The additional funds will also help diversify the portfolio in times of supply uncertainty; secure access to doses for delivery in 2021 and early 2022; and plan the scenarios and strategy to meet public health needs for 2022 and beyond...

.....

The COVAX Facility will deliver its 65 millionth vaccine dose this week. It should've been at least its 170 millionth. The time to donate excess doses is now

Statement by UNICEF Executive Director Henrietta Fore, as G7 countries gear up for June summit [Editor's text bolding] Editor's text bolding]

NEW YORK, 17 MAY 2021 – "The COVAX Facility – the global COVID vaccine equity scheme – will deliver its 65 millionth dose in the coming days. It should have been at least its 170 millionth. **By the time G7 leaders gather in the UK next month, and as a deadly second wave of COVID-19 will likely continue to sweep across India and many of its South Asian neighbours, the shortfall will near 190 million doses.**

"We have issued repeated warnings of the risks of letting down our guard and leaving low- and middle-income countries without equitable access to vaccines, diagnostics and therapeutics. We are concerned that the deadly spike in India is a precursor to what will happen if those warnings remain unheeded. While the situation in India is tragic, it is not unique. Cases are exploding and health systems are struggling in countries near – like Nepal, Sri Lanka and Maldives – and far, like Argentina and Brazil. The cost for children and families will be incalculable.

"The longer the virus continues to spread unchecked, the higher the risk of more deadly or contagious variants emerging.

"The clearest pathway out of this pandemic is a global, equitable distribution of vaccines, diagnostics and therapeutics. COVAX, led by the WHO, Gavi and CEPI, with UNICEF as implementing partner, represents such a pathway. But COVAX is undersupplied.

"Among the global consequences of the situation in India, a global hub for vaccine production, is a severe reduction in vaccines available to COVAX. Soaring domestic demand has meant that **140 million doses intended for distribution to low- and middle-income countries through the end of May cannot be accessed by COVAX. Another 50 million doses are likely to be missed in June.** This, added to vaccine nationalism, limited production capacity and lack of funding, is why the roll-out of COVID vaccines is so behind schedule.

"G7 leaders will be meeting next month with a potential emergency stop-gap measure readily available. New data analysis provided by Airfinity, the life sciences research facility, and commissioned by the UK National Committee for UNICEF, indicates that **G7 nations and 'Team Europe' group of European Union Member States could donate around 153 million vaccine doses if they shared just 20 per cent of their available supply over June, July and August.** Critically, they could do so while still meeting their commitments to vaccinate their own populations.

"While some G7 members have greater supply than others, and some have further advanced domestic rollouts, an immediate collective commitment to pool excess supply and share the burden of responsibility could buttress vulnerable countries against becoming the next global hotspot.

"Ultimately, the global vaccination race will be won when Member States make sustainable plans to fully fund and supply the COVAX Advance Market Commitment, while supporting the expansion of vaccine manufacturing capacity, including through proactive Intellectual Property licensing and technological transfer. These measures are critical, but they won't change anything overnight. **Sharing immediately available excess doses is a minimum, essential and emergency stop-gap measure, and it is needed right now.**"

.....

DG Okonjo-Iweala calls on WTO members to tackle vaccine inequity

Speaking to G20 leaders and the heads of international organizations on 21 May, Director-General Ngozi Okonjo-Iweala said WTO members could contribute to greater equity in the global distribution of COVID-19 vaccines by lowering supply chain barriers, fully using existing production capacity, and addressing issues related to intellectual property, access and innovation.

[No speech transcript posted; Editor's text bolding]

DG Okonjo-Iweala, who has described **equitable access to COVID-19 vaccines, diagnostics and therapeutics as "the moral and economic issue of our time,"** told the Global Health Summit, co-hosted by the European Commission and the Italian G20 Presidency, that the pandemic had made clear that "policymakers need to think of preparedness, response, and resilience as one interconnected package".

International cooperation on trade is important for all three elements of this package, she said, arguing that trade has been a "force for good" in the pandemic by enabling access to much-needed medical supplies. Even as the value of global merchandise trade shrank by more than 7% last year, trade in medical supplies increased by 16%, and by 50% for personal protective equipment, she noted.

With regards to the WTO's role in addressing the global vaccine scarcity, **DG Okonjo-Iweala said members could act on three fronts.**

"First, tackling supply chain issues holding back vaccine production, from export restrictions and excessive customs bureaucracy to problems accessing raw materials or hiring skilled workers. The WTO can help with supply chain monitoring and transparency."

The second action is helping manufacturers scale up by "keeping supply lines open and matching underused capacity with unmet needs," which DG Okonjo-Iweala declared as "necessary to save lives now".

"In the longer run, especially if COVID is with us for years, we need a more geographically diversified global vaccine manufacturing base. ... Having less than 0.2% of capacity in Africa is not a recipe for supply resilience."

The Director-General said the WTO would work with the World Health Organization, Gavi and the Coalition for Epidemic Preparedness Innovations on the COVAX vaccine manufacturing taskforce to advance equitable access.

Finally, DG Okonjo-Iweala said WTO members “must address issues related to technology transfer, knowhow and intellectual property,” including the proposed temporary waiver from WTO intellectual property rules for vaccines and other pandemic-related products.

“We must act now to get all our ambassadors to the table to negotiate a text,” she urged. “This is the only way we can move forward quickly, we can't move forward with speeches and polemics.”

“I am hopeful that by July we can make progress on a text and by our Twelfth Ministerial Conference in December, WTO members can agree on a pragmatic framework that offers developing countries near automaticity in access to health technologies, whilst also preserving incentives for research and innovation.”

.....

IFRC - [Asia: Vaccines run dry as COVID surges in Asia to new record death levels](#)

Asia Pacific, Bangladesh, India, Malaysia, Nepal, Philippines

Kuala Lumpur/Kathmandu/Delhi/Geneva, 21 May 2021 – Instant action is needed by governments and pharmaceutical companies to fix a COVID-19 vaccine supply crisis in Asia as countries run out of stocks while suffering grim record daily death tolls. Nepal ...

21 May 2021

IFRC - [Red Cross Red Crescent: We need new extraordinary steps to increase access to COVID-19 vaccines and we need them now](#)

The following statement can be attributed to the President of the International Federation of Red Cross and Red Crescent Societies, Francesco Rocca, and to the President of the International Committee of Red Cross, Peter Maurer: The International ...

18 May 2021

.....

[Despite Positive Efforts, Too Many Migrants Face Challenges Accessing COVID-19 Vaccines](#)

IOM / International Organization for Migration

2021-05-18 09:33

Geneva – Government policies, operational realities and administrative requirements like identification cards and residency permits may be **impeding access to national vaccination efforts for some migrants in 53 of the more than 160 countries** where the International Organization for Migration (IOM) has collected [information on access](#) so far. Irregular and undocumented migrants and those forcibly displaced are at particular risk.

“We have been impressed with efforts made in dozens of countries to make vaccination roll-outs as equitable as possible, but barriers to health services have been systemic since before the pandemic and remain a reality for too many migrants in too many places,” said IOM Director General António Vitorino.

"What we are seeing in some cases is a disconnect between what is being committed to on paper and what is actually happening in practice."

Some 47 countries have already taken concrete steps to ensure that migrants, including those in irregular situations, can access the vaccine. Many nations are still awaiting doses to begin their vaccination roll-outs. Even when they start, **IOM has identified more than 53 countries, territories or areas where current policies and operational realities will make vaccine access unattainable for the most vulnerable.**

Administrative, communication and logistical hurdles

IOM notes with particular concern close to 40 countries where administrative processes – such as requirements to present a national ID or valid residence permit, or to pre-register with national insurance schemes – may present an obstacle for some categories of migrants and forcibly displaced persons.

Other types of barriers have been identified in several locations, including prioritization of citizens and exclusion of non-nationals from vaccination campaigns; the lack of a “firewall” between health providers and immigration authorities which leads many migrants in irregular situations to fear arrest or deportation should they seek immunization; general vaccine hesitancy due to insufficient targeted outreach through linguistically and culturally appropriate channels; continued mobility as a challenge for vaccines requiring two doses, and **the need to have a smartphone, a computer or an internet connection to enroll...**

The report Migrant Inclusion in Covid-19 Vaccination Campaigns is available [here](#).

.....

Five Steps to Urgently Advance COVID-19 Vaccine Equity

The following was released jointly by PhRMA, ABPI, BIO, EFPIA, ICBA, IFPMA and Vaccines Europe.

WASHINGTON, D.C. (May 19, 2021) – Innovative vaccine manufacturers and biotech companies are at the forefront of the global effort to develop and manufacture COVID-19 vaccines. This massive effort is succeeding. After more than 200 clinical trials and nearly 300 partnerships and collaborations among manufacturers worldwide, production has increased, in just a few months from zero to 2.2 billion COVID-19 vaccine doses by the end of May with an astounding estimate of 11 billion doses by the end of 2021 (Airfinity data [here](#)). This will be enough doses to vaccinate the world’s adult population. Critically, however, COVID-19 vaccines currently are not equally reaching all priority populations worldwide.

Manufacturers, governments, and non-governmental organizations must work together to take urgent steps to further address this inequity. Immediate action must focus on stepping up responsible dose sharing and maximizing production without compromising quality or safety. To do so, innovative vaccine manufacturers and biotech companies commit to:

STEP UP DOSE SHARING:

:: Immediately work with governments that have significant domestic supplies of COVID-19 vaccine doses to share a meaningful proportion of their doses with low- and lower-middle-income countries in a responsible and timely way through COVAX or other efficient established mechanisms;

:: Expend every effort to make additional uncommitted COVID-19 vaccine doses available to low- and lower-middle income countries, through COVAX or other efficient established mechanisms.

CONTINUE TO OPTIMIZE PRODUCTION:

:: Undertake all practicable efforts to maximize COVID-19 vaccine output without compromising safety and quality, including through additional collaborations with partners that can produce significant quantities;

:: Work with governments and individual suppliers of raw materials and components to determine how to quickly and safely facilitate scale up needed for COVID-19 vaccine manufacturing.

CALL OUT TRADE BARRIERS TO BE ELIMINATED:

:: Identify trade barriers for critical input materials and support Coalition for Epidemic Preparedness Innovations' (CEPI's) effort to create an independent platform that would identify and address gaps in these inputs and facilitate voluntary matchmaking for fill and finish capacity through the newly established COVAX Supply Chain and Manufacturing Task Force

:: Urge governments, in coordination with the World Trade Organization (WTO), to eliminate all trade and regulatory barriers to export and to adopt policies that facilitate and expedite the cross-border supply of key raw materials, essential manufacturing materials, vaccines along with the prioritized movement of skilled workforce needed for COVID-19 vaccine manufacturing.

SUPPORT COUNTRY READINESS:

:: Partner with governments on COVID-19 vaccine deployment, particularly in low- and lower-middle income countries, to ensure that they are ready and able to deploy available doses within their shelf life;

:: Mitigate the risks to the production and deployment of other vaccines that remain vital to public health worldwide.

DRIVE FURTHER INNOVATION:

:: Prioritize the development of new COVID-19 vaccines, including vaccines effective against variants of concern;

:: Urge governments to guarantee unhindered access to pathogens (e.g. samples and sequences) of any COVID-19 variants to support the development of new vaccines and treatments.

.....
.....

Supply Chain/Procurement

World Bank – [Remarks of Mamta Murthi, Vice President for Human Development, at an Event on Vaccine Supply Chain and Manufacturing](#)

Date: May 19, 2021 *Statement*

[Editor's text bolding]

Thank you for giving me this opportunity and organizing this very informative and valuable summit. I was asked to give a perspective from the World Bank on the COVID-19 vaccine supply chain challenges. **I will say five things, mostly from the perspective of low- and middle-income countries (LICs/LMICs) who the World Bank finances.**

First, I want to say that we are very concerned about vaccine access for LICs/LMICs. Most available supply has been booked by rich countries. I want to reiterate the need to donate doses and do this in an equitable way. COVAX could play a role in allocating these doses.

Second, countries need to support manufacturing and supply chains by allowing free flow of final products and supplies. In this context, all free flow “inhibitors” should be done away with.

Third, lack of clarity around demand has to do with lack of transparency around contracts. Countries and manufacturers need to agree to be transparent around what has been committed to whom to clarify the true level of committed demand and what is open to discussion and negotiation.

Greater transparency into vaccine suppliers’ supply chain plans, such as reviewed and approved manufacturing sites, intended or approved affiliates (e.g., CMOs), and other contracting and licensing arrangements, would help facilitate contract discussions and a greater understanding of challenges facing suppliers during delivery phases. This would ultimately support the design of the best possible approaches.

Fourth, there is little grant funding (whether on the "push" or "pull" side) to "unblock" (through funding) constraints within the supply chain and for improving access to the vaccines in low income countries. The International Finance Corporation has been in discussions with various parties to encourage leveraging of grant funding through innovative and blended finance mechanisms. Investments from Multilateral Development Banks in potential bottleneck elements of the supply chain, e.g. production of glass vials and lipids, can make a huge difference.

Fifth, standardization. There was a lot of discussion about how standardization of regulatory reviews, vials, doses per vial, GMP approvals, and labelling could help. To this, we would add standardization of contracts. Developing standardized contracts, delivery and price terms for each supplier can help minimize bespoke contract efforts, normalize expectations across countries, and help improve transparency.

In the short term, there is a need to expand the existing production capacities, including repurposing of existing capacities targeted at delivering quality vaccines to the lower income economies. However, it is clear that **the current concentrated nature of the vaccine supply chains poses a great risk to low-income countries in accessing the vaccines**, not only to fight the COVID-19 pandemic but also to continue the fight against the other existing communicable disease challenges (HIV, etc.).

In the medium term, to increase resilience in developing countries, production and distribution capacities in emerging markets need to be strengthened. **Less than 5% of the vaccine manufacturing capacity is in Africa and Latin America. Engaging stakeholders to co-create commercially viable vaccine manufacturing especially in Africa needs to be a priority**

.....
.....

COVID Vaccination Documentation

[Committee on Tourism Ethics Recommends Responsible Use of Travel Certificates](#)

14 May 2021

World Tourism Organization (UNWTO)

Recommendation on COVID-19 Certificates for International Travel

The World Committee on Tourism Ethics, an independent and impartial body of the General Assembly of the World Tourism Organization (UNWTO), responsible for the promotion of the UNWTO Global Code of Ethics for Tourism, as well as the evaluation and monitoring of the implementation of its principles;

...Recognizing the urgent need to restart tourism in view of the summer tourist season in the Northern Hemisphere, which precedes the tourist season on the Southern Hemisphere, in order to mitigate the negative economic and social effects on tourism destinations, local populations and tourism workers;

Acknowledging the existence of various initiatives concerning health or COVID-19 related certificates and passports as well as a number of bilateral agreements between states with a view to facilitating the entry of vaccinated persons into their respective territories;

Considering international cooperation and global coordination as well as interoperability to be of highest importance for the implementation of these certificates worldwide;

Taking into account the right of national authorities to regulate the use of these certificates within their territories, in line with the principle of subsidiarity;

Calling upon the relevant national and international authorities to achieve a broad vaccine distribution and roll-out, by all useful means, while deploying a high degree of solidarity towards less advantaged countries and protecting local populations in this regard;

Noting that technological, sanitary, and legal matters related to COVID-19 certificates do not fall under the remit of this Committee.

Acknowledging the applicability to this context of the International Health Regulations (IHR) (2005), and the temporary recommendations issued by World Health Organization (WHO) under the IHR in reference to the public health emergency of international concern, encouraging States Parties to "implement coordinated, time-limited, risk-based, and evidence-based approaches for health measures in relation to international traffic" while considering the "limited (although growing) evidence about the performance of vaccines in reducing transmission".

Having in mind the principles and rules protective of personal data, which are of particular importance in the matter of health protection, notably the Article 12 of the Universal Declaration of Human Rights;...

Recommends that any COVID-19 certificate for international travel would have to meet the following conditions:

- 1. The certificate should be a unique document**, containing information on the vaccination status, and/or diagnostic (molecular, PCR and antigen) and/or information about recovery status;
- 2. The certificate should be limited in duration and its use should be discontinued** as soon as the World Health Organization no longer considers COVID-19 a Public Health Emergency of International Concern (PHEIC);
- 3. The certificate should be used primarily for international mobility;**
- 4. For a maximum accessibility, the certificate should be available both in digital and paper format;**

5. The certificate must ensure, in both formats, data protection and security, as well as the privacy of the holder. Said certificate must also provide a guarantee of authenticity to avoid fraud and misuses;

6. The certificate should be free of charge; international cooperation and governments should ensure the population's wide access to free vaccines and affordable tests;

7. The provision of vaccines and related certificates at destination countries should not form part of package tours or other similar products nor should such initiatives be supported by governments.

.....

EU Digital COVID Certificate: European Parliament and Council reach agreement on Commission proposal

Press release 20 May 2021

The Commission welcomes today's provisional political agreement between the European Parliament and the Council on the Regulation governing the EU Digital COVID Certificate.

...President Ursula von der Leyen said: "We are delivering on our commitment to have the EU Digital COVID Certificate up and running before the summer. European citizens are looking forward to travelling again, and today's agreement means they will be able to do so safely very soon.

The EU Digital COVID Certificate is free of charge, secure and accessible to all. It will cover vaccination, test and recovery offering different options to the citizens. It fully respects citizens' fundamental rights, including protection of personal data.

All EU citizens have a fundamental right to free movement in the EU. The EU Digital COVID Certificate, available in paper or digital format, will make it easier for Europeans to travel - whether to see their families and loved ones or to get some well-deserved rest...

The EU Digital COVID Certificate – key features

Following the agreement reached by the European Parliament and the Council, the EU Digital COVID Certificate:

:: will cover vaccination, test and recovery;

:: will be available in a digital and paper-based format, depending on the choice of the recipients, and contain a digitally signed QR code;

:: will be free of charge, be obtained easily and also available to persons vaccinated before the EU Digital COVID Certificate Regulation has entered into force;

:: may also be used by Member States for national purposes, if this is provided for in national law.

:: Member States shall refrain from imposing additional travel restrictions on the holders of an EU Digital COVID Certificate, unless they are necessary and proportionate to safeguard public health.

:: The Commission will also mobilise €100 million to support Member States in providing affordable tests.

Next Steps

The political agreement will now have to be formally adopted by the European Parliament and the Council. **The Regulation will enter into force on 1 July**, with a phasing-in period of six weeks for the issuance of certificates for those Member States that need additional time...

.....
.....

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

May 22, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 165M total confirmed cases; 3.4M total confirmed deaths

Global vaccines administered: 1.59B

Number of Countries: 26

COVAX First Allocations (Number of Doses): 73M

COVAX Delivered (Number of Doses): 15M

Other Delivered (Number of Doses): 24M

Total Delivered (Number of Doses): 40M

Total Administered (Number of Doses): 23M

.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 22 May 2021

Confirmed cases :: 165 772 430 [week ago: 161 513 458]

Confirmed deaths :: 3 437 545 [week ago: 3 352 109]

Vaccine doses administered: 1 448 242 899

.....

Weekly operational update on COVID-19 - 17 May 2021

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

- :: Surge capacity and procurement support in India
- :: Strengthening ambulance services as a part of the emergency response in Syria
- :: Contact tracing training in Kosovo
- :: Fiji boost its COVID-19 testing capabilities
- :: Supporting countries in the Americas to cope with oxygen supply and health worker shortages
- :: Monitoring implementation of Intra-Action Review recommendations in Indonesia
- :: Regular updates on WHO's resource requirements and funds received to support countries in implementing the COVID-19 Strategic Preparedness and Response Plan 2021, WHO/PAHO procurement of critical supplies, and implementation of the Unity Studies

Weekly epidemiological update on COVID-19 - 18 May 2021

Overview

Globally, in the past week, the number of new cases and deaths continued to decrease, although overall counts for both remained high with just over 4.8 million new cases and nearly 86 000 new deaths reported in the past week. All regions reported a decline in new cases this week with the exception of the Western Pacific where the number of new cases were similar to the previous week.

In this edition, a special focus update is provided on SARS-CoV-2 Variants of Interest (VOIs) and Variants of Concern (VOCs), including updates on the geographic distribution of VOCs B.1.1.7, B.1.351, P.1, and B.1.617.

Table 2: SARS-CoV-2 Variants of Concern and Variants of Interest, as of 18 May 2021

PANGO lineage Nextstrain clade GISAID clade	Alternate name	First detected in	Earliest samples	Characteristic spike mutations
Variants of Concern (VOCs)				
B.1.1.7 20I/501Y.V1 GR/501Y.V1	VOC 202012/01	United Kingdom	Sep 2020	69/70del, 144del, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
B.1.351 20H/501Y.V2* GH/501Y.V2	VOC 202012/02	South Africa	May 2020	D80A, D215G, 241/243del, K417N, E484K, N501Y, D614G, A701V
B.1.1.28.1, alias P.1 20J/501Y.V3 GR/501Y.V3	VOC 202101/02	Brazil	Nov 2020	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G H655Y, T1027I, V1176F
B.1.617* - G/452R.V3	-	India	Oct 2020	L452R, D614G, P681R, ± (E484Q, Q107H, T19R, del157/158, T478K, D950N)
Variants of Interest (VOIs)				
B.1.525 20A/S.484K G/484K.V3	-	Multiple countries	Dec 2020	Q52R, A67V, 69/70del, 144del, E484K, D614G, Q677H, F888L
B.1.427/B.1.429 20C/S.452R GH/452R.V1	CAL.20C/L452R	United States of America	Mar 2020	S13I, W152C, L452R, D614G
B.1.1.28.2, alias P.2 20B/S.484K GR	-	Brazil	Apr 2020	E484K, D614G, V1176F
B.1.1.28.3, alias P.3 - -	PHL-B.1.1.28	Philippines	Jan 2021	141/143del, E484K, N501Y, D614G, P681H, E1092K, H1101Y, V1176F
B.1.526 (+E484K/S477N) 20C GH	-	United States of America	Nov 2020	L5F, T95I, D253G, D614G, A701V, + (E484K or S477N)
B.1.616 - GH	-	France	Feb 2021	H66D, G142V, 144del, D215G, V483A, D614G, H655Y, G669S, Q949R, N1187D

* B.1.617 lineage is divided in three sublineages (B.1.617.1, B.1.617.2 and B.1.617.3). Findings for sublineages B.1.617.1 and B.1.617.2 were mainly used to declare B.1.617 a global VOC. Once more information becomes available, specific sublineages may be declared as a global VOI/VOC.

.....

.....

Draft landscape and tracker of COVID-19 candidate vaccines

21 May 2021 | Publication

The COVID-19 candidate vaccine landscape and tracker database compiles detailed information on COVID-19 vaccine candidates in development.

The landscape is updated regularly - twice a week (Tuesday and Friday, 17:00 CET).

Download: https://cdn.who.int/media/docs/default-source/blue-print/07.05.2021-novel-coronavirus_landscape_covid-19.xlsx.zip?sfvrsn=23955096_3&download=true














Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 April 2021

For 19 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[click on the link above for full scale view]

18 May 2021

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.	 Pfizer	BN162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.	 AstraZeneca	AZD1222	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Accepted core data Data for Covax sites expected in April 2021 onwards	Finalized Finalized: SK-Catalent Wuxi (DS) Other sites	16 April 2021 16 April 2021 30 April 2021 As submitted
3.	 AstraZeneca	AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.	 SERUM INSTITUTE OF INDIA PVT. LTD.	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.	 Janssen	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	Core data Additional sites: - Aspen South Africa - Other sites	Finalized (US + NL sites) - Ongoing - Awaited	12 March 2021 - May 2021 - As submitted
6.	 moderna	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021
7.	 Sinopharm / BIBP¹	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	07 May 2021
8.	 sinovac	SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	May 2021
9.	 THE GAMALEYA NATIONAL CENTER	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	"Rolling" submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Inspections in April, May and June 2021	Will be set after all data is submitted and inspections completed.
10.	 康希诺生物	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting May 2021		
11.	 NOVAVAX	NVX-CoV2373/Covovax	EMA	No pre-submission meeting yet.	Submitted EOI on 23 Feb	✓			
12.	 CureVAC	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	Submitted EOI on 12 April	Planned for 15 July 2021, based on company request			
13.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
14.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.				
15.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
16.	Bharat Biotech, India	COVAXIN	DCGI	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	Submitted EOI on 19/04/2021. More information required.	To be planned May-June 2021			
17.	Clover Biopharmaceuticals	SCB-2019	EMA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	In discussion on submission strategy and timelines				
18.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				
19.	 Sinopharm / WIBP²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells					

1. Beijing Bio-Institute of Biological Products Co Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

.....
.....

Statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) on safety signals related to the Johnson & Johnson/Janssen COVID-19 vaccine

19 May 2021 *Statement*

....The GACVS COVID-19 subcommittee met virtually on 11 May 2021 to review available information and data on thromboembolic events (blood clots) and thrombocytopenia (low platelets) after vaccination with the adenoviral vectored J&J vaccine. This condition is referred to as thrombosis with thrombocytopenia syndrome (TTS). Current evidence suggests a plausible causal association between the J&J COVID-19 vaccine and TTS. Clinically, the features of TTS following vaccination with this vaccine appear similar to those observed following another adenoviral vectored vaccine, the AstraZeneca COVID-19 vaccine. TTS does not appear to be associated with the mRNA COVID-19 vaccines. The exact mechanism by which this rare condition occurs is not fully understood. (1) To date, the only possible risks factors identified are age and gender (with more cases reported in women).

The subcommittee reviewed detailed surveillance data from the United States, which included stimulated passive surveillance and a small active surveillance cohort.

Based on a careful scientific review of the available information, the subcommittee came to the following conclusions and recommendations [*nine recommendations at title link above*]:

- The benefits of the J&J COVID-19 vaccine continue to outweigh the risks of TTS. As the only single dose COVID-19 vaccine approved for use to date, the vaccine may be an important tool for accessing difficult-to-reach populations, thus playing a key role in preventing infections and reducing deaths across the world...

...The GACVS COVID-19 subcommittee will continue to review the safety data from all COVID-19 vaccines and update any advice as necessary. Open, transparent, and evidence-based communication about the potential benefits and risks to recipients and the community is essential to maintain trust. WHO is carefully monitoring the rollout of all COVID-19 vaccines and will continue to work closely with countries to manage potential risks, and to use science and data to drive the response and update recommendations...

.....
.....

COVID Vaccine Developer/Manufacturer Announcements [*organizations from WHO EUL/PQ listing above*]

AstraZeneca

Press Releases

:: **AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan**

21 May 2021

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.

The Japanese Ministry of Health, Labour and Welfare granted the approval based on positive Phase III efficacy and safety data from the Oxford University-led clinical trial programme in the UK, Brazil and South Africa, and a Phase I/II trial in Japan...

Bharat Biotech, India

Press Releases - Website not responding at inquiry

BioCubaFarma – Cuba

Últimas Noticias

Intervención sanitaria en La Habana: Por todos y para el bien de todos

Resumen: Tras la presentación voluntaria de sujetos entre los 19 y 60 años, comenzó esta semana la intervención sanitaria con el candidato vacunal Abdala en los municipios Regla, Guanabacoa, Habana del Este y San Miguel del Padrón.

[Google translate: Summary: After the voluntary presentation of subjects between the ages of 19 and 60, the health intervention with the vaccine candidate Abdala began this week in the municipalities of Regla, Guanabacoa, Habana del Este and San Miguel del Padrón.]

CanSinoBIO

News

:: CanSinoBIO Receives EU GMP Certificate

Tianjin, May 21, 2021

CanSino Biologics Inc. ("CanSinoBIO") (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia), has been issued a Good Manufacturing Practice (GMP) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYEI)

The GMP certificate recognizes that CanSinoBIO's manufacturing facilities and quality control system meet the European Union's standards and guidelines, which paves the way for Convidecia™ to enter more markets globally...

Clover Biopharmaceuticals - China

News

:: Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern

May 18, 2021

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases - No new digest announcements identified

Moderna

Press Releases

[Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine](#) May 22, 2021

[Moderna and South Korea Explore Collaboration on mRNA Vaccines](#) May 22, 2021

[Ministry of Food and Drug Safety of South Korea \(MFDS\) Authorizes Moderna's COVID-19 Vaccine](#) May 21, 2021

[Japan's Ministry of Health, Labour and Welfare \(MHLW\) Approves Moderna's COVID-19 Vaccine](#) May 21, 2021

Novavax

Press Releases

[Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea](#) 5/22/2021

[Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants in the United Kingdom](#) 5/22/2021

[Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom](#) 5/22/2021

[Complete Trial Results Manuscript of Novavax COVID-19 Investigational Vaccine Posted to Preprint Server medRxiv](#) 5/21/2021

Pfizer

Recent Press Releases

[Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®](#)

Thursday, May 20, 2021 - 05:00am

:: New agreement to supply 900 million doses to the European Commission (EC), with option to request up to an additional 900 million doses

:: Additional dose deliveries beginning December 2021 through 2023

:: Pfizer and BioNTech have now committed a total of up to 2.4 billion doses of COMIRNATY® to the EC since the beginning of the pandemic

Serum Institute of India

NEWS & ANNOUNCEMENTS - No corporate announcements identified [Last release April 21.2021]

New York Times May 19, 2021

[A vaccine maker in India signals it won't export doses before year's end, slowing aid to the world's poorest.](#)

By Sameer Yasir

The vaccination woes of some of the world's poorest nations will continue as the [Serum Institute of India](#), a crucial manufacturing pillar in the plan to supply two billion doses of Covid-19 vaccines to low-income countries, signaled that it would not be able to provide vaccines beyond India before the year's end.

The revelation, tucked into a statement by the vaccine manufacturing giant that attempted to deflect mounting criticism, was another setback for Covax, the global vaccine partnership for the poor. It is already more than 140 million doses behind schedule, and the Serum Institute's announcement suggested it was all but impossible to meet the goal of two billion doses by the end of the year.

The announcement once again underscored the glaring contrast of inequality: As some of the richer nations tout levels of vaccinations that allow them to reopen their society, most of the poorer nations have barely gotten a start.

"We continue to scale up manufacturing and prioritize India," the Serum Institute of India said in the statement on Tuesday. "We also hope to start delivering to Covax and other countries by the end of this year."...

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....
.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 22 May 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view from 2021-05-02 to date]



14

vaccines licensed or approved
for emergency/conditional use



6

vaccines in WHO's Emergency
Use Listing



12.1bn

doses secured globally



\$2-\$40

reported vaccine price range
per dose



4.06bn

doses secured & optioned
through COVAX *



71.7M

doses shipped through COVAX
to 125 countries

Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
2021-05-03	COVAX AMC	Multilateral	mRNA-1273	Moderna	Moderna


Our World in Data

Coronavirus (COVID-19) Vaccinations

Daily COVID-19 vaccine doses administered per 100 people, May 21, 2021

Our World in Data

Shown is the rolling 7-day average per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).




Source: Official data collated by Our World in Data - Last updated 22 May, 14:30 (London time)
OurWorldInData.org/coronavirus • CC BY

Dec 15, 2020 May 21, 2021

Share of the population fully vaccinated against COVID-19, May 21, 2021

Our World in Data

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.



Source: Official data collated by Our World in Data - Last updated 22 May, 14:30 (London time)
OurWorldInData.org/coronavirus • CC BY

Dec 27, 2020 May 21, 2021

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee

:: [Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Announcement](#)

FDA

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements/Selected Details

[May 21, 2021 - Coronavirus \(COVID-19\) Update: May 21, 2021](#)

[May 19, 2021 - FDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available](#)

[May 19, 2021 - FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination](#)

[May 18, 2021 - Coronavirus \(COVID-19\) Update: May 18, 2021](#)

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

May 21, 2021 • Press Briefings

[Remarks by President Biden at Signing of the COVID-19 Hate Crimes Act](#)

May 20, 2021 • Speeches and Remarks

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

May 18, 2021 • Press Briefings

[FACT SHEET: Biden-Harris Administration is Providing at least 80 million COVID-19 Vaccines for Global Use, Commits to Leading a Multilateral Effort toward Ending the Pandemic](#)

May 17, 2021 • Statements and Releases


Today, the President reaffirmed his commitment to leading an international and coordinated vaccination effort, announcing that the U.S. will donate 80 million U.S. vaccines – the 60 million doses of AstraZeneca vaccines previously announced and at least an additional 20 million doses of U.S. authorized vaccines by the end of June. The U.S. will continue to donate from our excess supply as that supply is delivered to us...

[Remarks by President Biden on the COVID-19 Response and the Vaccination Program](#)

May 17, 2021 • Speeches and Remarks

.....

COVID Data Tracker [U.S.] May 8, 2021

Total Vaccine Doses Delivered 354,914,965 Administered 281,595,351 <small>Learn more about the distribution of vaccines.</small>	People Vaccinated	At Least One Dose	Fully Vaccinated
	Total	161,278,336	127,778,250
	% of Total Population	48.6%	38.5%
	Population ≥ 12 Years of Age	161,197,822	127,769,851
	% of Population ≥ 12 Years of Age	57.5%	45.6%
	Population ≥ 18 Years of Age	156,852,134	125,950,707
	% of Population ≥ 18 Years of Age	60.8%	48.8%
	Population ≥ 65 Years of Age	46,524,478	40,195,084
	% of Population ≥ 65 Years of Age	85.1%	73.5%
<small> About these data</small>			
<small>CDC Data as of: May 21, 2021 6:00am ET. Posted: Friday, May 21, 2021 8:49 PM ET</small>			

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[**News: EMA issues advice on use of sotrovimab \(VIR-7831\) for treating COVID-19 \(new\)**](#)

CHMP, Last updated: 21/05/2021

[**News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 17-20 May 2021 \(new\)**](#)

CHMP, Last updated: 21/05/2021

[**News: More flexible storage conditions for BioNTech/Pfizer's COVID-19 vaccine \(new\)**](#)

CHMP, Last updated: 17/05/2021

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

[**ECDC releases new dashboard on SARS-CoV-2 variants**](#)

News - 19 May 2021

A new dashboard released by ECDC now provides an overview of the proportion of SARS-CoV-2 variants of concern and variants of interest among sequenced samples in European Union (EU) and European Economic Area (EEA) countries, as well as sequencing volumes. It complements the data published in ECDC's weekly country overview report.

Data are sourced from The European Surveillance System (TESSy) (weekly reports submitted to ECDC by countries) and the GISAID EpiCoV database (extracted weekly). The maps within the dashboard will be updated every Thursday afternoon, and the data behind the dashboard are available to download.

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

News

Statement 21 May 2021

[Statement by President von der Leyen following the Global Health Summit](#)

Press release 21 May 2021

[Team Europe launches new financing platform to support health security and resilience in Africa](#)

Speech 21 May 2021

[Speech by Commissioner Reynders on the provisional political agreement on the EU Digital COVID Certificate](#)

Press release 21 May 2021

[Global leaders adopt agenda to overcome COVID-19 crisis and avoid future pandemics](#)

Leaders of the G20 committed today to a series of actions to accelerate the end of the COVID-19 crisis everywhere and better prepare for future pandemics, at a summit co-hosted by European Commission President Ursula von der Leyen and Italian Prime Minister Mario Draghi,.

Press release 21 May 2021

[€1 billion Team Europe initiative on manufacturing and access to vaccines, medicines and health technologies in Africa](#)

European Commission President Ursula von der Leyen announced today at the G20 Global Health Summit in Rome a Team Europe initiative on manufacturing and access to vaccines, medicines and health technologies in Africa.

Press release 20 May 2021

[EU Digital COVID Certificate: European Parliament and Council reach agreement on Commission proposal](#)

The Commission welcomes today's provisional political agreement between the European Parliament and the Council on the Regulation governing the EU Digital COVID Certificate.

Press release 20 May 2021

[Coronavirus: Commission signs a third contract with BioNTech-Pfizer for an additional 1.8 billion doses](#)

Today, the European Commission signed a third contract with the pharmaceutical companies BioNTech and Pfizer.

.....
.....

Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

See Africa CDC below.

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

Single-dose Sputnik Light vaccine approved for use in Nicaragua

Press release, 20.05.2021

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the approval of the Russian single-dose Sputnik Light vaccine against coronavirus by the Ministry of Health of the Republic of Nicaragua.

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered.

The data was obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021...

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
22 May 2021, 08:00 IST
(GMT+5:30)

(↑↓ Status change since
yesterday)

Active (11.12%)

2923400 (104525↓)

Discharged (87.76%)

23070365 (357630↑)

Deaths (1.12%)

295525 (4194↑)

COVID-19 Vaccination
as on : 22 May 2021,
08:00 IST (GMT+5:30)

Total Vaccination : 19,33,72,819 (14,58,895 ↑)

19.05.2021

Revised COVID-19 Clinical Management Protocol Algorithm (Adults)

Government of India – Press Information Bureau

Latest Press Releases

COVID-19 Vaccination Update- Day 127

- :: Cumulative Vaccine Coverage exceeds 19.49 Crore
- :: Nearly 1cr beneficiaries of age group 18-44 Vaccinated so far
- :: More than 15.5 lakh Vaccine Doses administered today till 8 pm

Posted On: 22 MAY 2021

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

No new digest content identified.

.....

.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[See China CDC section below]

.....

.....

.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 19 May 2021

:: Come and join the virtual launch of the Polio Eradication Strategy 2022-2026, at an online event on Thursday 10 June 2021 (at 2pm, Central European Summer Time). More information, including registration details, are available [here](#), where you will find the 'Save the Date'.

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- :: Afghanistan: five cVDPV2 cases
- :: Pakistan: one cVDPV2 case
- :: China: one cVDPV3 positive environmental sample
- :: Liberia: two cVDPV2 positive environmental samples
- :: Mali: one cVDPV2 case
- :: Nigeria: one cVDPV2 case and one cVDPV2 positive environmental sample

Statement following the Twenty-Eighth IHR Emergency Committee for Polio

21 May 2021 Statement

The twenty-eighth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 4 May 2021 with Committee members and advisers attending via video conference, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and

circulating vaccine-derived polioviruses (cVDPV). The following IHR States Parties provided an update at the video conference on the current situation in their respective countries: Afghanistan, Kenya, Pakistan, Senegal, South Sudan and Tajikistan...

Conclusion

The Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months. The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC, but concludes that the current situation is extraordinary, with clear ongoing substantial risk of international spread and utmost need for coordinated international response. The Committee considered the following factors in reaching this conclusion:

Continued risk of WPV1 international spread

Based on the following factors, the risk of international spread of WPV1 appears to be currently very high:

:: Despite the reported drop in the number of WPV-1 cases, **there is geographically widespread transmission in Pakistan and Afghanistan** as evidenced by positive environmental samples.

:: Isolation of long chain viruses in both countries indicates the possibility of missed transmission in the hard-to-reach population groups.

:: The **ongoing inaccessibility in many provinces of Afghanistan** has led to the increase in size of highly susceptible populations which continues to drive higher transmission; to date about three million children were missed during all the nation-wide rounds in 2020 and 2021 (the highest in southern Afghanistan), and the cohort of missed children continues to rapidly grow (https://polioeradication.org/wp-content/uploads/2021/05/Afghanistan_NEAP_2021.pdf).

:: **Inconsistent vaccination campaigns quality in critical areas of Pakistan and Afghanistan**, including Karachi, Quetta Block and accessible areas of southern Afghanistan.

:: Ongoing barriers to reach missed children in the core reservoirs of Pakistan and Afghanistan, including refusals to polio vaccination.

:: The complicated context of WPV eradication activities in Afghanistan and Pakistan created by the need to simultaneously respond to cVDPV2 and COVID-19.

:: **The second wave of COVID-19 that appears to be currently underway in Pakistan, Afghanistan and many polio-affected countries, making the interventions more complex and difficult.**

Rising risk of cVDPV2 international spread:

Based on the following factors, the risk of international spread of cVDPV2 appears to be currently very high:

:: Despite the reported decline in the number of cVDPV2 cases, the risk of international spread of cVDPV2 remains quite high as evidenced by recent importation in Senegal (never infected before) and Kenya (re-importation from Somalia).

:: The most updated analyses performed by the GPLN on international spread (Oct – Dec 2020), indicates cVDPV2 exportation from one country to another on 17 occasions.

:: **The cVDPV2 transmission in Afghanistan has spread to areas that have been inaccessible for vaccination campaigns due to local bans for more than two years. This appears to be driving the intense transmission there, with continued high risk of national and international spread.**

:: The ever-widening gap in population intestinal mucosal immunity in young children since the withdrawal of OPV2 in 2016.

:: The same factors regarding the COVID-19 pandemic as mentioned above...

...Based on the current situation regarding WPV1 and cVDPV, and the reports provided by affected countries, the **Director-General accepted the Committee's assessment on 21 May 2021 and determined that the situation relating to poliovirus continues to constitute a PHEIC, with respect to WPV1 and cVDPV...**

.....
.....

WHO/OCHA Emergencies

Editor's Note:

Continuing with this edition, we include information about the last apparent update evident on the WHO emergency country webpages, recognizing almost universal and significant interims since last update regardless of the level of the emergency listed.

WHO Grade 3 Emergencies [to 22 May 2021]

Democratic Republic of the Congo - *No new digest announcements identified [Last apparent update: 3 May 2021]*

Mozambique floods - *No new digest announcements identified [Last apparent update: 3 November 2020]*

Nigeria - *No new digest announcements identified [Last apparent update: 29 Jun 2020]*

Somalia - *No new digest announcements identified [Last apparent update: 13 July 2020]*

South Sudan - *No new digest announcements identified [Last apparent update: 4 February 2020]*

Syrian Arab Republic - *No new digest announcements identified [Last apparent update: 24 October 2020]*

Yemen - *No new digest announcements identified [Last apparent update: 30 June 2020]*

.....

WHO Grade 2 Emergencies [to 22 May 2021]

Burkina Faso –

:: Renforcer les capacités du personnel de santé dans la prise en charge des victimes d...
21 mai 2021

Afghanistan - *No new digest announcements identified [Last apparent update: 5 July 2020]*

Angola - *No new digest announcements identified [Last apparent update: 16 March 2021]*

Burundi - *No new digest announcements identified [Last apparent update: 04 July 2019]*

Cameroon - *No new digest announcements identified [Last apparent update: 12 March 2020]*

Central African Republic - *No new digest announcements identified [Last apparent update: 12 June 2018]*

Ethiopia - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Iran floods 2019 - *No new digest announcements identified [Last apparent update: 2 March 2020]*

Iraq - *No new digest announcements identified [Last apparent update: 512 May 2021]*

Libya - *No new digest announcements identified [Last apparent update: 7 October 2019]*

Malawi - No new digest announcements identified [Last apparent update: 22 April 2021]
Measles in Europe - No new digest announcements identified [Last apparent update: 26-04-2021]
MERS-CoV - No new digest announcements identified [Last apparent update: 8 July 2019]
Mozambique - No new digest announcements identified [Last apparent update: 03 November 2020]
Myanmar - No new digest announcements identified [Last apparent update: 29 March 2021]
Niger - No new digest announcements identified [Last apparent update: 16 avril 2021]
occupied Palestinian territory - No new digest announcements identified [Last apparent update: 4 September 2019]
HIV in Pakistan - No new digest announcements identified [Last apparent update: 27 August 2019]
Sao Tome and Principe Necrotizing Cellulitis (2017) - No new digest announcements
Sudan - No new digest announcements identified [Last apparent update: 24 June 2020]
Ukraine - No new digest announcements identified [Last apparent update: 1 May 2019]
Zimbabwe - No new digest announcements identified [Last apparent update: 10 May 2019]

.....

WHO Grade 1 Emergencies [to 22 May 2021]

Chad - No new digest announcements identified [Last apparent update: 30 June 2018]
Djibouti - No new digest announcements identified [Last apparent update: 25 novembre 2020]
Kenya - No new digest announcements identified [Last apparent update: 21 May 2021]
Mali - No new digest announcements identified [Last apparent update: 3 May 2017]
Namibia - viral hepatitis - No new digest announcements identified [Last apparent update: 20 July 2018]
Tanzania - No new digest announcements identified [Last apparent update: 21 October 2019]

.....

.....

UN OCHA – Current Emergencies

Current Corporate Emergencies

Ethiopia

No new digest announcements identified

.....

.....

WHO & Regional Offices [to 22 May 2021]

<https://www.who.int/>

21 May 2021

Statement

Statement following the Twenty-Eighth IHR Emergency Committee for Polio

21 May 2021

News release

G20 leaders boost support of the Access to COVID-19 Tools (ACT) Accelerator but urgent and immediate action is needed to maintain momentum

20 May 2021

Joint News Release

[New international expert panel to address the emergence and spread of zoonotic diseases](#)

International organizations have come together to launch a new One Health High-Level Expert Panel to improve understanding of how diseases with the potential to trigger pandemics, emerge and spread.

The panel will advise four international organizations - the Food and Agriculture Organization of the United Nations (FAO); the World Organisation for Animal Health (OIE); the United Nations Environment Programme (UNEP); and the World Health Organization (WHO) - on the development of a long-term global plan of action to avert outbreaks of diseases like H5N1 avian influenza; MERS; Ebola; Zika, and, possibly, COVID-19. Three quarters of all emerging infectious diseases originate in animals.

It will operate under the One Health Approach, which recognizes the links between the health of people, animals, and the environment and highlights the need for specialists in multiple sectors to address any health threats and prevent disruption to agri-food systems.

Key first steps will include systematic analyses of scientific knowledge about the factors that lead to transmission of a disease from animal to human and vice versa; development of risk assessment and surveillance frameworks; identification of capacity gaps as well as agreement on good practices to prevent and prepare for zoonotic outbreaks...

20 May 2021

Departmental news

[Programmatic innovations to address challenges in tuberculosis prevention and care during the COVID-19 pandemic](#)

20 May 2021

Departmental news

[New report highlights global progress on reducing HIV, viral hepatitis and sexually transmitted infections and signals need for renewed efforts to reach 2030 targets](#)

20 May 2021

Statement

[Support to countries' equitable and resilient recovery from the pandemic towards the health SDGs: The 2021 SDG3 GAP progress report](#)

19 May 2021

News release

[WHO issues new guidance for research on genetically modified mosquitoes to fight malaria and other vector-borne diseases](#)

19 May 2021

News release

[World Health Assembly to focus on ending COVID-19 pandemic and preparing for next one](#)

19 May 2021

Statement

[Statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety \(GACVS\) on safety signals related to the Johnson & Johnson/Janssen COVID-19 vaccine](#)

19 May 2021

Departmental news

[Developing global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for 2022-2030](#)

18 May 2021

Departmental news

[WHO and UNICEF launch new tools for the promotion of adolescent mental health](#)

17 May 2021

Joint News Release

[Long working hours increasing deaths from heart disease and stroke: WHO, ILO](#)

.....

[Weekly Epidemiological Record, Vol. 96, No. 20, pp. 164–175 21 May 2021](#)

:: Evidence review – Public health measures in the aviation sector in the context of COVID-19: quarantine and isolation (21 May 2021)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

No new digest content identified

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: [Health in Europe podcast: tackling inequities to build fairer, healthier societies](#) 21-05-2021

:: [Integrated screening for infectious diseases: a success story from Georgia](#) 21-05-2021

:: [WHO/Europe's governing board decides to hold virtual Regional Committee session](#) 20-05-2021

:: [COVID-19: A fragile progress](#) 20-05-2021

:: [Q&A: COVID-19 variants and what they mean for countries and individuals](#) 20-05-2021

WHO Eastern Mediterranean Region EMRO

:: [COVID-19 posing unprecedented threat on war-torn Yemen](#) 20 May 2021

WHO Western Pacific Region

:: [Hong Kong SAR \(China\) eliminates rubella](#) 21 May 2021

.....

.....

CDC/ACIP [U.S.] [to 22 May 2021]

<http://www.cdc.gov/media/index.html>
<https://www.cdc.gov/vaccines/acip/index.html>
Latest News Releases, Announcements
No new digest content identified

.....

MMWR News Synopsis Friday, May 21, 2021

:: Characteristics of COVID-19 Cases and Outbreaks at Child Care Facilities — District of Columbia, July–December 2020
:: The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 years — United States, May 2021 (Early Release May 14, 2021)
:: Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 (Early Release May 14, 2021)
:: Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–April 10, 2021 (Early Release May 18, 2021)

.....

Coronavirus Disease 2019 (COVID-19)- CDC

Selected Resources

5/21/21 Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 21 May 2021 06:00:00 EST

5/21/21 COVID Data Tracker Recent Updates - 2021-05-20 - The new COVID-19 Hospitalizations and Disease Severity tab shows trends in hospitalizations and disease severity among patients hospitalized with COVID-19 in a large subset of hospitals across the U.S.

5/20/21 The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021

.....

.....

Africa CDC [to 22 May 2021]

<http://www.africacdc.org/>

News

African Ministers of Health Back AU's New PMT and 4D Partnership Tech Strategies to fight COVID-19

ADDIS ABABA, 18 May 2021: African Ministers of Health have committed to support the Africa Centres for Disease Control and Prevention's (Africa CDC), new initiatives to double down on the ongoing continental recovery from the COVID-19 pandemic at an emergency virtual summit held on 8 th May...

In connection with the PMT strategy, ministers welcomed the proposal for waivers and exemptions to Intellectual Property (IP) rights tabled by the World Trade Organization (WTO), and the decision of the US to support the proposal, as part of the effort to globalise the manufacturing of vaccines and ensure equity in access and availability worldwide.

In addition to the PMT strategy, the new 4D Partnership was also announced – a platform for multi-disciplinary, multi-dimensional, multi-departmental and multi-directional collaboration in Africa, powered by artificial intelligence and machine learning, big data and home-grown innovation. The 4D Partnership is a collaboration of several AU organs including the Commission's Department of Education, Science, Technology & Innovation; the Department of Agriculture, Rural Development, Blue Economy & Sustainable Environment; the Department of Economic Development, Trade, Industry & Mining; the African Continental Free Trade Area (AfCFTA) Secretariat; and the Africa CDC.

The platform will strengthen harmonisation of use cases in health, research, education, climate response and trade, for example, the Africa CDC's Trusted Travel and Trusted Vaccines platforms. Other programs, such the Africa Pathogen Genomics Initiative (Africa PGI), will benefit from the multi-stakeholder networks of the AU Science and Technology Framework, and help to accelerate integrated diagnostic, socioeconomic, immunological and genomic data streams to better analyse patterns of disease mutations and variants spread in Africa...

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

CCDC Weekly - [Weekly Reports: Current Volume \(3\)](#)

2021-05-21 / No. 21

[PDF of this issue](#)

:: [Outbreak Reports: COVID-19 Outbreak Caused by Contaminated Packaging of Imported Cold-Chain Products — Liaoning Province, China, July 2020](#)

:: [Methods and Applications: Development of a PDRA Method for Detection of the D614G Mutation in COVID-19 Virus — Worldwide, 2021](#)

:: [Notes from the Field: The First Reported Case of COVID-19 and Plasmodium ovale Malaria Coinfection — Guangdong Province, China, January 2021](#)

:: [Notes from the Field: Two Imported Cases of New Variant COVID-19 First Emerging from Brazil — Guangdong Province, China, April 30, 2021](#)

:: [Recommendations: Technical Vaccination Recommendations for COVID-19 Vaccines in China \(First Edition\)](#)

To date, five coronavirus disease 2019 (COVID-19) vaccines have been conditionally approved for market authorization or granted emergency use authorization in China by the National Medical Products Administration (NMPA). Three inactivated COVID-19 vaccines and one adenovirus-vectored vaccine were granted conditional approval, as phase III clinical trial data for these four conditionally-approved vaccines have demonstrated protective efficacy levels that meet requirements of NMPA's Guidelines for Clinical Evaluation of COVID-19 vaccine (interim version) and also meet requirements recommended by the World Health Organization (WHO) in their COVID-19 Vaccines Target Product Profile. Adverse event surveillance data from clinical trials, emergency use, and large-scale vaccination of key populations have demonstrated that the approved COVID-19 vaccines have excellent safety profiles. One recombinant subunit COVID-19 vaccine was approved for emergency use, as phase II clinical trial results showed good immunogenicity and safety of the recombinant subunit COVID-19 vaccine (CHO cell).

Based on clinical trial data of the NMPA-approved domestic vaccines and the epidemiological characteristics of COVID-19, the COVID-19 Vaccine Technical Working Group of China CDC drafted

technical vaccination recommendations. The National Immunization Advisory Committee reviewed, discussed, and refined the recommendations. The National Health Commission accepted and published these recommendations ([1](#))...

National Health Commission of the People's Republic of China [to 22 May 2021]

<http://en.nhc.gov.cn/>

News

May 22: Daily briefing on novel coronavirus cases in China

On May 21, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 10 new cases of confirmed infections.

Single-dose vaccine now available

2021-05-20

Several cities across China have recently started offering residents a single-dose COVID-19 vaccine in addition to the two-dose inactivated vaccines that were already widely used in the country's vaccination drive.

At the temporary vaccination station in Shanghai's Xuhui district on Wednesday, a new CanSino sign was placed alongside the Sinovac and Sinopharm ones as vaccine providers of the day...

National Medical Products Administration – PRC [to 22 May 2021]

<http://english.nmpa.gov.cn/news.html>

News

Over 449m doses of COVID-19 vaccines administered in China

2021-05-21

More than 449.5 million doses of COVID-19 vaccines had been administered in China as of May 19, the National Health Commission said on May 20.

.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 22 May 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 22 May 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 22 May 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 22 May 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 22 May 2021]

<https://carb-x.org/>

News

05.19.2021 |

[CARB-X is funding Basilea Pharmaceutica to develop a new class of antibiotics to treat drug-resistant Gram-negative bacteria](#)

CARB-X is awarding Basilea Pharmaceutica International (SIX: BSLN), Basel, Switzerland, up to US \$2.7 million to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram-negative bacteria, often called 'superbugs' because they have developed resistance at an alarming pace to existing antibiotics, kill an estimated 700,000 people each year around the world.

05.18.2021 |

[CARB-X is funding Summit Therapeutics to develop a new antibiotic to treat multidrug-resistant infections caused by carbapenem-resistant Enterobacteriaceae \(CRE\)](#)

CARB-X is awarding Summit Therapeutics, (NASDAQ: SMMT) headquartered in Cambridge, MA, USA, with its Discuva subsidiary located in Cambridgeshire, UK, up to US\$4.1 million in non-dilutive funding to develop a first-in-class antibiotic to treat multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections including those caused by serious human pathogens such as *Escherichia coli* and *Klebsiella pneumoniae*. Under the award, Summit could receive additional funding of up to \$3.7 million from CARB-X if project milestones are achieved, subject to available funds. The award will help the company progress the SMT-738 antibiotic project through preclinical and Phase 1a clinical development.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 22 May 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – May 2021*** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 22 May 2021]

<http://cepi.net/>

Latest News

Former Assistant Secretary for Preparedness and Response Dr Nicole Lurie appointed US Director at CEPI, the global partnership to develop vaccines to stop future epidemics

Dr Lurie to lead CEPI's work in the US and strengthen CEPI's collaboration with the USA

News 20 May 2021

Survey launched by CEPI to track multinational vaccine manufacturing capacity for use in future epidemics and pandemics

The landscaping exercise aims to build the first of-its-kind map tracking cross-regional vaccine production capabilities.

News 19 May 20

DARPA – Defense Advanced Research Projects Agency [to 22 May 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 22 May 2021]

<https://dukeghic.org/>

WEEKLY COVID VACCINE RESEARCH UPDATE

Last dated update: FRIDAY, April 16, 2021

EDCTP [to 22 May 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

No new digest content identified.

Emory Vaccine Center [to 22 May 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 22 May 2021]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

FDA [to 22 May 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements / Selected Details

[May 21, 2021 - Coronavirus \(COVID-19\) Update: May 21, 2021](#)

[May 20, 2021 - FDA In Brief: FDA Solicits Public Feedback on Discussion Paper as Part of its Ongoing Commitment to Patient Safety](#)

[May 19, 2021 - FDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available](#)

[May 19, 2021 - FDA In Brief: FDA Advises Against Use of SARS-CoV-2 Antibody Test Results to Evaluate Immunity or Protection From COVID-19, Including After Vaccination](#)

[May 18, 2021 - Coronavirus \(COVID-19\) Update: May 18, 2021](#)

[May 18, 2021 - FDA In Brief: Science Forum Highlights Regulatory Science Advancements in Protecting and Promoting Public Health](#)

[See U.S. COVID Actions above for detail]

Fondation Merieux [to 22 May 2021]

<http://www.fondation-merieux.org/>

News, Events

Mérieux Foundation co-organized event

[AMR in times of COVID-19 webinar](#)

May 28, 2021 - Virtual Event

Gavi [to 22 May 2021]

<https://www.gavi.org/>

News Releases

21 May 2021

[Global leaders renew their commitment to address urgency of COVID-19 pandemic](#)

:: At today's Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC)

:: Italy committed EUR 300 million to the Gavi COVAX AMC, which will count towards COVAX's goal of procuring 1.8 billion COVID-19 vaccine doses for lower-income economies in 2021.

:: In addition, France, Germany, Italy, The Netherlands, Norway, Spain and Switzerland – as part of Team Europe – pledged to share a combined total of over 100 million vaccine doses with middle- and low-income economies, boosting short term supplies.

21 May 2021

[Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX](#)

:: The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021

:: Doses will be delivered to self-financing participants of the COVAX Facility as well as lower-income economies eligible to be supported by the Gavi COVAX Advance Market Commitment (AMC)

:: Gavi CEO Seth Berkley: "This agreement means the COVAX Facility is able to offer participants yet another safe and effective tool against the pandemic. I welcome Johnson & Johnson's commitment to equitable access and to expanding global manufacturing. As a one dose vaccine, the J&J vaccine has particular relevance for places with difficult infrastructure, making it a very important addition to the portfolio."

18 May 2021

[Go Give One campaign gives public the opportunity to support access to COVID-19 vaccines for lower-income countries](#)

:: Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic

:: The platform will give businesses a chance to match employee and customer contributions

GHIT Fund [to 22 May 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
May 18, 2021

[GHIT Fund Announces New Investments: A Total of 960 Million Yen in Drugs for Leishmaniasis and Diagnostics for Buruli Ulcer and Chagas Disease](#)

Global Fund [to 22 May 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

[G20 Reaffirms Commitment to ACT-A to Fight COVID-19](#)

21 May 2021

G20 leaders and heads of international and regional organizations reaffirmed their commitment to fight pandemics and support the Access to COVID-19 Tools (ACT) Accelerator –a ground breaking collaboration of global partners to accelerate the development, production and equitable delivery of new tests, treatments, vaccines and health supplies worldwide.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 22 May 2021]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 22 May 2021]

<http://www.hillemanlabs.org/>

Website not responding at inquiry

Human Vaccines Project [to 22 May 2021]

<http://www.humanvaccinesproject.org/media/press-releases/>

No new digest content identified.

IAVI [to 22 May 2021]

<https://www.iavi.org/newsroom>

PRESS RELEASES/FEATURES

May 21, 2021

[In Memoriam: Dr. Deepak Gaur](#)

May 19, 2021

[We need to prioritize African women in HIV vaccine research — its future success depends on it](#)

This HIV Vaccine Awareness Day, we join the call for women to be at the center of the HIV response to lead their own solutions.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 22 May 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 22 May 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Asia Pacific, Bangladesh, India, Malaysia, Nepal, Philippines

Asia: Vaccines run dry as COVID surges in Asia to new record death levels

Kuala Lumpur/Kathmandu/Delhi/Geneva, 21 May 2021 – Instant action is needed by governments and pharmaceutical companies to fix a COVID-19 vaccine supply crisis in Asia as countries run out of stocks while suffering grim record daily death tolls. Nepal ...

21 May 2021

Global

Red Cross Red Crescent: We need new extraordinary steps to increase access to COVID-19 vaccines and we need them now

The following statement can be attributed to the President of the International Federation of Red Cross and Red Crescent Societies, Francesco Rocca, and to the President of the International Committee of Red Cross, Peter Maurer: The International ...

18 May 2021

India

India: Red Cross helps as cyclone strikes double blow in world COVID hotspot

Kuala Lumpur/Delhi, 17 May – Red Cross is urgently responding to keep people safe as a major cyclone sweeps up the west coast of India, threatening millions already reeling from a world-record COVID-19 surge. In recent days, India has seen a slight red ...

17 May 2021

Institut Pasteur [to 22 May 2021]

<https://www.pasteur.fr/en/press-area>

Press Info

21.05.2021

ART Plus Combination Immunotherapy Expands Natural Killer Cells That Facilitate Control of HIV

Yerkes National Primate Research Center researchers in collaboration with Institut Pasteur have determined a...

IOM / International Organization for Migration [to 22 May 2021]

<http://www.iom.int/press-room/press-releases>

News

Despite Positive Efforts, Too Many Migrants Face Challenges Accessing COVID-19 Vaccines

2021-05-18 09:33

Geneva – Government policies, operational realities and administrative requirements like identification cards and residency permits may be impeding access to national vaccination efforts for some migrants in 53 of the more than 160 countries where the International Organization...

[See COVID above for detail]

IRC International Rescue Committee [to 22 May 2021]

<http://www.rescue.org/press-release-index>

Media highlights [Selected]

Press Release

No new digest content identified.

IVAC [to 22 May 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 22 May 2021]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

International Vaccine Institute and FII Institute sign MOU to cooperate on scientific research and publication

The agreement is an effort to further scientific research in infectious diseases and make knowledge more accessible through advocacy and joint publications.

May 19, 2021 – SEOUL, South Korea, RIYADH, Saudi Arabia – The International Vaccine Institute (IVI) and the Future Investment Initiative Institute (FII-I) signed a memorandum of understanding (MOU) to increase awareness and muster support to tackle infectious diseases. IVI and FII-I will endeavor to pursue strategic collaborations with each other, working together on topics that create value for both organizations within healthcare, more specifically within the field of infectious diseases...

JEE Alliance [to 22 May 2021]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

Johns Hopkins Center for Health Security [to 22 May 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/Médecins Sans Frontières [to 22 May 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

No new digest content identified.

National Academy of Medicine - USA [to 22 May 2021]

<https://nam.edu/programs/>

Selected News/Programs

Upcoming Events:

May 25, 2021

International Workshop on COVID-19 Lessons to Inform Pandemic Influenza Response, Day 3: Lessons Learned Across Fields

Time: 8:00 AM

This global public workshop will convene international experts, thought-leaders, and other stakeholders to discuss the emerging evidence on these unprecedented actions related to COVID-19 that could inform and advance pandemic and seasonal influenza vaccine preparedness efforts and subsequent response.

News

G20 Scientific Expert Panel, Co-Chaired by NAM President, Identifies Key Recommendations to Address Global Health Crises

May 21, 2021

[See Milestones above for detail]

National Vaccine Program Office - U.S. HHS [to 22 May 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 22 May 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

No new digest content identified.

UN OCHA Office for the Coordination of Humanitarian Affairs [to 22 May 2021]

<https://www.unocha.org/>

Press Releases

No new digest content identified.

PATH [to 22 May 2021]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 22 May 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 22 May 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

21 May 2021

Support to countries' equitable and resilient recovery from the pandemic towards the health SDGs: The 2021 SDG3 GAP progress report

21 May 2021

The world can only beat AIDS by ending the inequalities that drive the epidemic

20 May 2021

A grandmother's transformative love for her transgender grandchild

19 May 2021

Integrated services and inclusion key to eliminating mother-to-child HIV transmission in Dominica

19 May 2021

UNAIDS Executive Director engages with women leaders and young women in Namibia

18 May 2021

UNAIDS and its partners implement Partnership to Accelerate COVID-19 Testing in Madagascar

UNDP United Nations Development Programme [to 22 May 2021]

<http://www.undp.org/content/undp/en/home/presscenter.html>

Latest from News Centre

No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 22 May 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

Statement attributable to UN High Commissioner for Refugees Filippo Grandi on the need to end US COVID-19 asylum restrictions

20 May 2021

I appeal to the government of the United States to swiftly lift the public health-related asylum restrictions that remain in effect at the border and to restore access to asylum for the people whose lives depend on it, in line with international legal and human rights obligations...

UNICEF [to 22 May 2021]

<https://www.unicef.org/media/press-releases>

Selected Press Releases, Statements

Press release 05/20/2021

As deadly surge of COVID-19 sweeps across South Asia, UNICEF calls for US\$164 million to help save lives

KATHMANDU, 21 May 2021 – UNICEF urgently requires US\$164 million to procure oxygen and testing supplies, medical equipment, personal protective equipment and infection prevention and control material to help save lives amid a deadly wave of COVID-19 across South Asia.

The region, home to almost 2 billion people, accounts for half of known new infections globally. Over three new COVID-19 infections are being recorded every second. Mortality in the region is rising sharply, with more than three people dying every minute due to COVID-19.

"The sheer scale and speed of this new surge of COVID-19 is outstripping countries' abilities to provide life-saving treatment," said George Laryea-Adjei, UNICEF Regional Director for South Asia. "Hospitals are overwhelmed, there is an acute lack of oxygen and other critical medical supplies, and there is a real risk of fragile health systems collapsing."...

Statement 05/17/2021

The COVAX Facility will deliver its 65 millionth vaccine dose this week. It should've been at least its 170 millionth. The time to donate excess doses is now

Statement by UNICEF Executive Director Henrietta Fore, as G7 countries gear up for June summit
[See COVID above for detail]

Unitaid [to 22 May 2021]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccination Acceptance Research Network (VARN) [to 22 May 2021]

<https://vaccineacceptance.org/news.html#header1-2r>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 22 May 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Social media conversations and attitudes in the UK towards COVID-19

12 May 2021

These reports provide insights on key topics of conversation around coronavirus in the UK with a focus on five preventive behaviours (social distancing, self-isolation, lockdown, wearing masks, and a coronavirus vaccine).

Vaccine Education Center – Children's Hospital of Philadelphia [to 22 May 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 22 May 2021]

<https://wellcome.ac.uk/news>
News and reports
No new digest content identified.

The Wistar Institute [to 22 May 2021]
<https://www.wistar.org/news/press-releases>
Press Releases
May. 20, 2021

[The Wistar Institute and Other Top U.S. Cancer Centers Call for Urgent Action to Get Cancer-Preventing HPV Vaccination Back on Track](#)

PHILADELPHIA – May 20, 2021 – The Wistar Institute has partnered with doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers to issue a joint statement urging the nation's physicians, parents and young adults to get the human papillomavirus (HPV) vaccination back on track.

"Vaccination is critical to preventing human papillomavirus infection that can lead to cervical cancer, head and neck cancer and other preventable, HPV-related cancers. Yet pandemic-related safety concerns are discouraging people across the country from receiving these important, safe and effective HPV vaccines," said Dario Altieri, M.D., Wistar president and CEO, Cancer Center director, and the Robert & Penny Fox Distinguished Professor. "It is vital that we remain vigilant against these preventable cancers and ensure HPV vaccination of our children and young adults and continue to schedule routine cancer screenings and check-ups each year."

Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic have caused a significant vaccination gap and lag in vital preventive services among U.S. children and adolescents—especially for the HPV vaccine...

WFPHA: World Federation of Public Health Associations [to 22 May 2021]
<https://www.wfpha.org/>
Latest News

[2020-2021 Annual Report Is Now Available!](#)

May 20, 2021

2020-2021 Annual Report Is Now Available! Here, review our major initiatives and activities from the past 12 months, explore our achievements and have an insight of our plan for the next year.

[The Winners & the Losers in COVID-19 Immunization](#)

May 19, 2021

The Winners & the Losers in COVID-19 Immunization COVID-19 has exposed vulnerabilities in our society. To fight the virus, the global public health workforce must advocate for vulnerable communities who are disproportionately harmed in this...

World Bank [to 22 May 2021]
<http://www.worldbank.org/en/news/all>
Selected News, Announcements

[Remarks by World Bank Group President David Malpass at the Global Health Summit Co-Hosted by the European Commission and Italy, as Chair of the G20](#)

Excellencies, Thank you, Prime Minister Draghi, and President von der Leyen. I share the intensity and deep emotions of previous speakers in combatting the pandemic. Together, we need to find faster and...

Date: May 21, 2021 Type: Speeches and Transcripts

Remarks of Mamta Murthi, Vice President for Human Development, at an Event on Vaccine Supply Chain and Manufacturing

Thank you for giving me this opportunity and organizing this very informative and valuable summit. I was asked to give a perspective from the World Bank on the COVID-19 vaccine supply chain challenges...

Date: May 19, 2021 Type: Statement

[See COVID above for detail]

World Customs Organization – WCO [to 22 May 2021]

<http://www.wcoomd.org/>

Latest News – Selected Items

No new digest content identified.

World Organisation for Animal Health (OIE) [to 22 May 2021]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

Press Releases

No new digest content identified.

WTO - World Trade Organisation [to 22 May 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

DG Okonjo-Iweala calls on WTO members to tackle vaccine inequity

Speaking to G20 leaders and the heads of international organizations on 21 May, Director-General Ngozi Okonjo-Iweala said WTO members could contribute to greater equity in the global distribution of COVID-19 vaccines by lowering supply chain barriers, fully using existing production capacity, and addressing issues related to intellectual property, access and innovation.

[See COVID above for detail]

Webinar to address delivery of medical technologies, vaccines to their final destination

21 May 2021

A panel of experts will explore on 26 May 2021 the factors determining the successful delivery of medical technologies and vaccines to their final destination. The webinar will discuss the lessons learned so far and will consider how to undertake a practical and forward-looking approach. The event forms part of a series of events to mark the 25th anniversary of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)...

The webinar is an integral part of the “Virtual Course on Trade and Public Health with a Special Focus on the COVID-19 Pandemic” and is open to the public. It will take place on 26 May 2021, from 13:00 to 15:00 (CET).

Registration for the webinar is available [here](#).

The full programme of the event is available [here](#).

The event will be live streamed through the [WTO YouTube channel](#).

.....

ARM [Alliance for Regenerative Medicine] [to 22 May 2021]
[Press Releases - Alliance for Regenerative Medicine \(alliancerm.org\)](#)
Press Releases
No new digest content identified.

BIO [to 22 May 2021]
<https://www.bio.org/press-releases>
Press Releases
[BIO Cheers Biden Announcement to Share 20 Million Doses of Vaccines with Developing Nations](#)
May 18, 2021
"The White House's decision to send Covid-19 vaccines to countries in need is an important step to ensuring people around the globe have access to lifesaving shots and ending this global pandemic. "As part of BIO's recently-proposed Global "SHARE"..."

DCVMN – Developing Country Vaccine Manufacturers Network [to 22 May 2021]
<http://www.dcvmn.org/>
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 22 May 2021]
<https://internationalbiotech.org/news/>
News
[EU Healthcare Biotech Policy Priorities for SMEs](#)
3 JUN. 2021 -- 03 Jun. 2021
Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With EU-level strategies within Pharmaceuticals, Intellectual Property, Orphan Medicines and the proposed 'European Health Emergency Preparedness and Response Authority (HERA)'...

IFPMA [to 22 May 2021]
<http://www.ifpma.org/resources/news-releases/>
Selected Press Releases, Statements, Publications
[Five steps to urgently advance COVID-19 vaccine equity](#)
19 May 2021
[See COVID above for detail]

PhRMA [to 22 May 2021]
<http://www.phrma.org/>

Selected Press Releases, Statements

ICYMI: PhRMA president and CEO Stephen J. Uhl joins other industry leaders for a conversation on COVID-19 vaccines with Axios

May 21, 2021

On May 19, Axios hosted an event discussing the unprecedented development of COVID-19 vaccines and the road ahead.

Five Steps to Urgently Advance COVID-19 Vaccine Equity

May 19, 2021

Released jointly by PhRMA, ABPI, BIO, EFPIA, ICBA, IFPMA and Vaccines Europe.

[See COVID above for detail]

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 5: E371-433 May 2021

<https://journalofethics.ama-assn.org/issue/ending-hiv-epidemic>

Ending the HIV Epidemic

A human immunodeficiency virus (HIV) epidemic began in the United States in the 1970s. "Ending the HIV Epidemic: A Plan for America" was launched in October 2019 by the US Department of Health and Human Services, with the goal of stopping the spread of HIV by 2030. Accomplishing this goal demands not only expanding existing programs, but recognizing and responding to clinically, ethically, socially, and culturally relevant features of contemporary patients' experiences of stigma, oppression, and living with HIV. This issue considers ethical and clinical complexities patients and clinicians encounter in HIV care today.

American Journal of Infection Control

May 2021 Volume 49 Issue 5 p533-656

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

May 2021 Volume 60 Issue 5 p595-736

<http://www.ajpmonline.org/current>

Research Articles

[Reviewed earlier]

American Journal of Public Health

May 2021 111(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 104 (2021): Issue 4 (Apr 2021)

<https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml>

Perspective Piece

The COVID-19 Pandemic in Peru: What Went Wrong?

Alvaro Schwalb and Carlos Seas

DOI: <https://doi.org/10.4269/ajtmh.20-1323>

Articles Open access

Contact Tracing and the COVID-19 Response in Africa: Best Practices, Key Challenges, and Lessons Learned from Nigeria, Rwanda, South Africa, and Uganda

Jean B. Nachega, Rhoda Atteh, Chikwe Ihekweazu, Nadia A. Sam-Agudu, Prisca Adejumo, Sabin Nsanzimana, Edson Rwagasore, Jeanine Condo, Masudah Paleker, Hassan Mahomed, Fatima Suleman, Alex Riolexus Ario, Elsie Kiguli-Malwadde, Francis G. Omaswa, Nelson K. Sewankambo, Cecile Viboud, Michael J. A. Reid, Alimuddin Zumla, and Peter H. Kilmarx

DOI: <https://doi.org/10.4269/ajtmh.21-0033>

Refugee Settlements and Cholera Risks in Uganda, 2016–2019

Godfrey Bwire, Christopher Garimoi Orach, Freda Loy Aceng, Sam Emmanuel Arianitwe, David Matseketse, Edson Tumushere, Issa Makumbi, Allan Muruta, Rebecca D. Merrill, Amanda Debes, Mohammad Ali, and David A. Sack

DOI: <https://doi.org/10.4269/ajtmh.20-0741>

Home Administration of CVD 103-HgR: A Live Attenuated Oral Cholera Vaccine

R. Paul Duffin, Michael Delbuono, Lawrence Chew, James Johnstone, Volker Niedan, Pascal Schwarz, Paul Shabram, and Amish A. Patel

DOI: <https://doi.org/10.4269/ajtmh.20-1223>

Annals of Internal Medicine

May 2021 Volume 174, Issue 5

<http://annals.org/aim/issue>

Original Research

[A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine](#)

Nadine C. Salisch, PhD, Kathryn E. Stephenson, MD, MPH, Kristi Williams, BSN, PhD, Freek Cox, PhD, ... [et al.](#)

Pages:585–594

Reviews

[The Proportion of SARS-CoV-2 Infections That Are Asymptomatic - A Systematic Review](#)

FREE

Daniel P. Oran, AM, Eric J. Topol, MD

Pages:655–662

[Major Update: Remdesivir for Adults With COVID-19 - A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points](#)

FREE

Anjum S. Kaka, MD, Roderick MacDonald, MS, Nancy Greer, PhD, Kathryn Vela, MLIS, ... [et al.](#)

Special Articles

[SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn](#)

FREE

Mark Connors, MD, Barney S. Graham, MD, H. Clifford Lane, MD, Anthony S. Fauci, MD

Pages:687–690

[Clinical Decision Making During the COVID-19 Pandemic](#)

FREE

Joshua P. Metlay, MD, PhD, Katrina A. Armstrong, MD, MSCE

Pages:691–693

[COVID-19 Vaccine: Practical Clinical Considerations](#)

FREE

Christine Laine, MD, MPH, Deborah Cotton, MD, MPH, Darilyn V. Moyer, MD

Ideas and Opinions

[Preparing for COVID-19 Vaccination: A Call to Action for Clinicians on Immunization Information Systems](#)

FREE

Andrew B. Trotter, MD, MPH, Elizabeth K. Abbott, MPH, Rebecca Coyle, MEd, ... [et al.](#)

Pages:695–697

[Addressing Mistrust About COVID-19 Vaccines Among Patients of Color](#)

FREE

Douglas J. Opel, MD, MPH, Bernard Lo, MD, Monica E. Peek, MD, MPH, MS

Pages:698–700

[Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts](#)

FREE

Laura E. Riley, MD, Denise J. Jamieson, MD, MPH

Pages:701–702

Artificial Intelligence – An International Journal

Volume 295 June 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/295/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 22 May 2021)

[No new digest content identified]

BMJ Global Health

May 2021 - Volume 6 - Suppl 2

https://gh.bmj.com/content/6/Suppl_2

The future of vaccine safety

Editorial

[**Vaccine safety: looking forward and back**](#) (19 May, 2021)

Alexander Muir Walker, Walter A Orenstein

Analysis

[**Vaccine safety issues at the turn of the 21st century**](#) (19 May, 2021)

Laura Conklin, Anders Hviid, Walter A Orenstein, Andrew J Pollard, Melinda Wharton, Patrick Zuber

[**Novel vaccine safety issues and areas that would benefit from further research**](#) (19 May, 2021)

Daniel A Salmon, Paul Henri Lambert, Hanna M Nohynek, Julianne Gee, Umesh D Parashar, Jacqueline E Tate, Annelies Wilder-Smith, Kenneth Y Hartigan-Go, Peter G Smith, Patrick Louis F Zuber

[**Evolving pharmacovigilance requirements with novel vaccines and vaccine components**](#) (19 May, 2021)

Patrick L F Zuber, Marion Gruber, David C Kaslow, Robert T Chen, Brigitte K Giersing, Martin H Friede

[**Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions**](#) (19 May, 2021)

Caitlin Dodd, Nick Andrews, Helen Petousis-Harris, Miriam Sturkenboom, Saad B Omer, Steven Black

[**Vaccine safety in the next decade: why we need new modes of trust building**](#) (19 May, 2021)

Heidi J. Larson, Isabelle Sahinovic, Madhava Ram Balakrishnan, Clarissa Simas

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 22 May 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 22 May 2021)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 22 May 2021)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 22 May 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 22 May 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 22 May 2021)

[Knowledge, attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a cross-sectional study](#)

This study determined the knowledge, attitudes, and practice regarding COVID-19 and assessed the acceptance of the COVID-19 vaccine among healthcare workers and the general population.

Authors: Muhammed Elhadi, Ahmed Alsoufi, Abdulmueti Alhadi, Amel Hmeida, Entisar Alshareea, Mawadda Dokali, Sanabel Abodabos, Omaymah Alsadiq, Mohammed Abdelkabir, Aimen Ashini, Abdulhamid Shaban, Saja Mohammed, Nehal Alghudban, Eman Bureziza, Qasi Najah, Khawla Abdulrahman...

Citation: BMC Public Health 2021 21:955

Content type: Research

Published on: 20 May 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 22 May 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

June 2021 - Volume 26 - 3

<https://ebm.bmj.com/content/26/3>

EBM opinion and debate

[Primary care: Building capacity in evidence-based medicine in low-income and middle-income countries: problems and potential solutions](#) (22 November, 2019)

Peter J Gill, Shabana M Ali, Yasmin Elsobky, Raymond C Okechukwu, Tatiane B Ribeiro, Augusto Cesar Soares dos Santos Junior, Daniel Umpierre, Georgia C Richards

BMJ Open

May 2021 - Volume 11 - 5

<https://bmjopen.bmj.com/content/11/5>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99, Number 5, May 2021, 321-404

<https://www.who.int/bulletin/volumes/99/5/en/>

[Reviewed earlier]

Cell

May 13, 2021 Volume 184 Issue 10 p2525-2796

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 47, Issue 3 Pages: 297-410 May 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 109, Issue 5 Pages: 1159-1362 May 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

Volume 43 Issue 3 p431-650, e57-e96

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 2, April 2021
<https://journals.sagepub.com/toc/ctja/18/2>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 22 May 2021]
[No new digest content identified]

Contemporary Clinical Trials

Volume 103 April 2021
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/103/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 2 / April 2021
<https://www.liebertpub.com/toc/crispr/4/2>
[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 2, June 2021
<https://link.springer.com/journal/40142/volumes-and-issues/9-2>
[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2021 - Volume 34 - Issue 3
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020
<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>
[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 1 Pages: i, 1-54 March 2021
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 31, Issue 4, 2021
<http://www.tandfonline.com/toc/cdip20/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 1 - February 2021
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[Reviewed earlier]

Disasters

Volume 45, Issue 2 Pages: 253-497 April 2021
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 22 Issue 5 5 May 2021
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 5—May 2021
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 34 March 2021
<https://www.sciencedirect.com/journal/epidemics/vol/34/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>
[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 2 Pages: 1-48 March–April 2021
<https://onlinelibrary.wiley.com/toc/25782363/current>
Research ethics and pandemics • IRBs and AI research
[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue 2, April 2021

<https://academic.oup.com/eurpub/issue/31/2>

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (3) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 22 May 2021]

[No new digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 22 May 2021]

[Global genomic pathogen surveillance to inform vaccine strategies: a decade-long expedition in pneumococcal genomics](#)

Vaccines are powerful agents in infectious disease prevention but often designed to protect against some strains that are most likely to spread and cause diseases. Most vaccines do not succeed in eradicating t...

Authors: Stephen D. Bentley and Stephanie W. Lo

Citation: Genome Medicine 2021 13:84

Content type: Review

Published on: 17 May 2021

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 1 March 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Public Health

Volume 16, Issue 5 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

Special Issue: The Contested Global Politics of Pleasure and Danger: Sexuality, Gender, Health and Human Rights; Guest Editors: Carmen H. Logie, Amaya Perez-Brumer and Richard Parker

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 22 May 2021]

[COVID-19 and future pandemics: a global systems approach and relevance to SDGs](#)

The COVID-19 pandemic is adversely impacting modern human civilization. A global view using a systems science approach is necessary to recognize the close interactions between health of animals, humans and the...

Authors: Tharanga Thoradeniya and Saroj Jayasinghe

Citation: Globalization and Health 2021 17:59

Content type: Debate

Published on: 21 May 2021

[How does globalization affect COVID-19 responses?](#)

The ongoing COVID-19 pandemic has highlighted the vast differences in approaches to the control and containment of coronavirus across the world and has demonstrated the varied success of such approaches in min...

Authors: Steve J. Bickley, Ho Fai Chan, Ahmed Skali, David Stadelmann and Benno Torgler

Citation: Globalization and Health 2021 17:57

Content type: Research

Published on: 20 May 2021

Health Affairs

Vol. 40, No. 3 March 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

March 2021 / Nursing Homes, COVID-19 & More

[Reviewed earlier]

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 2 - April 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 3, April 2021

<https://academic.oup.com/heapol/issue/36/3>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 22 May 2021]

[No new digest content identified]

Human Gene Therapy

Volume 32, Issue 9-10 / May 2021

<https://www.liebertpub.com/toc/hum/32/9-10>

[New issue; No digest content identified]

Humanitarian Exchange Magazine

Number 78, October 2020

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

Disability inclusion in humanitarian action

by HPN October 2020

The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies' lack of engagement with organisations of persons with disabilities. Simone Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a 'participation revolution', building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox's Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide's approach to mainstreaming protection and inclusion, while Pauline Thivillier

and Valentina Shafina outline IRC's Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD's SADI approach.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 5, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 22 May 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 22 May 2021]

[No new digest content identified]

International Health

Volume 13, Issue 3, May 2021

<https://academic.oup.com/inthealth/issue/13/3>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 5 (2021) May 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/76>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 2, April 2021

<https://academic.oup.com/ije/issue>

[New issue; No digest content identified]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

Volume 106 p1-430

<https://www.ijidonline.com/current>

Editorial

Vaccination against SARS-CoV-2 should be included in childhood vaccination programs

Eskild Petersen, Philippe Buchy

Published online: April 29, 2021

An Asia-Pacific study on healthcare workers' perceptions of, and willingness to receive, the COVID-19 vaccination

Nicholas W.S. Chew, Clare Cheong, Gwyneth Kong, ...Arvind K. Sharma, Roger C. Ho, Vijay K. Sharma

Published online: March 26, 2021

p52-60

JAMA

May 11, 2021, Vol 325, No. 18, Pages 1813-1912

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

Sivan Haia Perl, MD; Atara Uzan-Yulzari, MSc; Hodaya Klainer, BSc; et al.

free access has active quiz

JAMA. 2021;325(19):2013-2014. doi:10.1001/jama.2021.5782

This prospective study investigated whether antibodies from SARS-CoV-2 immunization of nursing mothers transferred to infants as a potentially protective effect.

Viewpoint

Digital Health Passes in the Age of COVID-19Are “Vaccine Passports” Lawful and Ethical?

Lawrence O. Gostin, JD; I. Glenn Cohen, JD; Jana Shaw, MD, MPH

free access

JAMA. 2021;325(19):1933-1934. doi:10.1001/jama.2021.5283

This Viewpoint discusses digital health passes (DHPs) that would grant access to work, entertainment, shopping, and travel with confirmation of COVID-19 immunity, and the scientific, legal, ethical, and equity considerations that must be worked through for DHPs to be considered effective and fair.

Viewpoint

Incorporating Adult Evidence Into Pediatric Research and PracticeBayesian Designs to Expedite Obtaining Child-Specific Evidence

Srinivas Murthy, MD, CM, MHSc; Patricia Fontela, MD; Scott Berry, PhD

free access

JAMA. 2021;325(19):1937-1938. doi:10.1001/jama.2020.25007

This Viewpoint proposes ways to use bayesian methods to integrate evidence from adult clinical trials into the conduct, interpretation, and application of pediatric trials to generate scientifically robust and clinically actionable data for the care of children at a pace comparable with that for adults

JAMA Network

COVID-19 Update May 22, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

May 2021, Vol 175, No. 5, Pages 449-544

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

May 2021 - Volume 19 - Issue 5

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

EDITORIALS

PRISMA 2020: a reporting guideline for the next generation of systematic reviews

Brennan, Sue E.; Munn, Zachary

JBIR Evidence Synthesis. 19(5):906-908, May 2021.

Journal of Adolescent Health

Volume 68 Issue 6 p1025-1222

<https://www.jahonline.org/current>

[New issue; No digest content identified]

Journal of Artificial Intelligence Research

Vol. 71 (2021)

<https://www.jair.org/index.php/jair>

[New issue; No digest content identified]

Journal of Community Health

Volume 46, issue 3, June 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-3>

[Reviewed earlier]

Journal of Development Economics

Volume 150 May 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/150/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 1-2, February-April 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

May 2021 - Volume 75 - 5

<https://jech.bmj.com/content/75/5>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 1 Pages: 1-81 February 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 1, February 2021

<https://muse.jhu.edu/issue/43951>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 3, June 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 223, Issue 7, 1 April 2021

<https://academic.oup.com/jid/issue/223/7>

[Reviewed earlier]

Journal of Medical Ethics

May 2021 - Volume 47 - 5

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 2 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

Volume 233 p1-300

<http://www.jpeds.com/current>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 22 May 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

May/June 2021 - Volume 27 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 1, March 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-1>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

May 2021 Volume 18 Issue 178

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 3, April 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

May 2021; Volume 95, Issue 10

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

May 15, 2021 Volume 397 Number 10287 p1781-1858, e12-e14

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[Rethinking vaccine hesitancy among minority groups](#)

Mishal S Khan, Sameen A Mohsin Ali, Addy Adelaine, Abraar Karan

[Priorities for COVID-19 research response and preparedness in low-resource settings](#)

GloPID-R, UKCDR, and COVID-19 Clinical Research Coalition Cross-Working Group on COVID-19 Research in LMICs

Correspondence

[Refugee access to COVID-19 vaccines in Lebanon](#)

Nadine K Jawad, Lina Abu Taweeleh, Jad A Elharake, Nicole Khamis, Osaid Alser, Fatima M Karaki, Layla Aboukhater

The Lancet Child & Adolescent Health

May 2021 Volume 5 Number 5 p309-384, e12-e18

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

May 2021 Volume 3 Number 5 e274-e329

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

May 2021 Volume 9 Number 5 e558-e720

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

May 2021 Volume 21 Number 5 p579-742, e110-e140

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

May 2021 Volume 6 Number 5 e260-e345

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

May 2021 Volume 9 Number 5 p435-544, e47-e50

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 5, May 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-5>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 41 Issue 4, May 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 1 Pages: 1-327 March 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 593 Issue 7859, 20 May 2021

<https://www.nature.com/nature/volumes/593/issues/7859>

[New issue; No digest content identified]

Nature Biotechnology

Volume 39 Issue 5, May 2021

<https://www.nature.com/nbt/volumes/39/issues/5>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 22 May 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 5, May 2021

<https://www.nature.com/ng/volumes/53/issues/5>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 5, May 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/5>

Editorial | 20 May 2021

[The value of evidence synthesis](#)

Science is a cumulative enterprise, and systematic evidence synthesis is invaluable for appraising what is known and what is not known on a specific research question. We strongly encourage the submission of systematic reviews and meta-analyses to Nature Human Behaviour.

Article | 30 March 2021

[Socioeconomic impacts of COVID-19 in low-income countries](#)

Recent phone survey data from Ethiopia, Malawi, Nigeria and Uganda reveals the breadth of the socioeconomic impacts of the COVID-19 pandemic on individuals and households.

Anna Josephson, Talip Kilic, Jeffrey D. Michler

Nature Medicine

Volume 27 Issue 5, May 2021

<https://www.nature.com/nm/volumes/27/issues/5>

[Reviewed earlier]

Nature Reviews Genetics

Volume 22 Issue 5, May 2021

<https://www.nature.com/nrg/volumes/22/issues/5>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 5, May 2021

<https://www.nature.com/nri/volumes/21/issues/5>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 5, May 2021

<https://www.nature.com/nrd/volumes/20/issues/5>

[Reviewed earlier]

New England Journal of Medicine

May 20, 2021 Vol. 384 No. 20

<http://www.nejm.org/toc/nejm/medical-journal>

Original Articles

[Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant](#)

Shabir A. Madhi, Ph.D., et al for the NGS-SA Group, and the Wits-VIDA COVID Group*

Conclusions

A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, [NCT04444674. opens in new tab](#); Pan African Clinical Trials Registry number, [PACTR202006922165132. opens in new tab](#)).

[Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant](#) [Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant](#)

Vivek Shinde, M.D., M.P.H., et al for the 2019nCoV-501 Study Group*

Conclusions

The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, [NCT04533399. opens in new tab](#).)

Pediatrics

Vol. 147, Issue 5 1 May 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 5, May 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-5>

[Reviewed earlier]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 22 May 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 22 May 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 22 May 2021)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 22 May 2021]

Vaccine hesitancy among paediatric nurses: Prevalence and associated factors

Usue Elizondo-Alzola, Mireia G. Carrasco, Laia Pinós, Camila Andrea Picchio, Cristina Rius, Elia Diez
Research Article | published 19 May 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0251735>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 22 May 2021]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

May 11, 2021; vol. 118 no. 19

<https://www.pnas.org/content/118/19>

Opinion

Leading scientists discuss current issues

Opinion: Compound risks and complex emergencies require new approaches to preparedness

A. Kruczkiewicz, J. Klopp, J. Fisher, S. Mason, S. McClain, N. M. Sheekh, R. Moss, R. M. Parks, and C. Braneon

PNAS May 11, 2021 118 (19) e2106795118; <https://doi.org/10.1073/pnas.2106795118>

Increasingly, we face compounding and interrelated environmental, socioeconomic, and political crises. Yet our approaches to these problems are often siloed, fragmented, and inadequate. The current pandemic, for instance, continues to collide with a number of other threats to human life and livelihoods. These include violent conflicts, displacement, insect swarms, droughts, heat waves, and structural inequality in the form of racism and gender discrimination. We believe we are at a critical juncture, faced with a need and responsibility to redesign institutions to be proactive, agile, and socially just when confronted with increasingly likely compound risks...

Prehospital & Disaster Medicine

Volume 36 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 146 May 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/146/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

26 May 2021 Volume 288 Issue 1951

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 193 Pages 1-156 (April 2021)

<https://www.sciencedirect.com/journal/public-health/vol/193/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 13, Issue 3, November 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 3, May 2021

<https://journals.sagepub.com/toc/phrg/136/3>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 6, May 2021

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 2, April 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 22 May 2021]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

19 May 2021

Pharmaceutical procurement among public sector procurers in CARICOM

Original research | English |

Risk Analysis

Volume 41, Issue 5 Pages: 701-841 May 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus and COVID-19: Part 1

Editorial Free Access

Global Systemic Risk and Resilience for Novel Coronavirus and COVID-19

Desheng Dash Wu, Jade Mitchell, James H. Lambert

Pages: 701-704

First Published: 17 May 2021

Original Research Articles Open Access

Exploring Risks of Human Challenge Trials For COVID-19

David Manheim Ph.D., Witold Więcek Ph.D., Virginia Schmit Ph.D., Josh Morrison, 1Day Sooner Research Team

Pages: 710-720

First Published: 04 May 2021

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 22 May 2021]

[No new digest content identified]

Science

21 May 2021 Vol 372, Issue 6544

<http://www.sciencemag.org/current.dtl>

[New issue; No digest content identified]

Science Translational Medicine

19 May 2021 Vol 13, Issue 594

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 276 May 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/276/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 22 May 2021]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 41 May–June 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/41/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 5 Pages: i-iv, 503-608 May 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 20 Pages 2731-2810 (12 May 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/20>

Short communication Open access

[Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis](#)

Vincent Daniels, Kunal Saxena, Craig Roberts, Smita Kothari, ... Linda Niccolai

Pages 2731-2735

Review article Abstract only

[The safety of BCG revaccination: A systematic review](#)

Samantha Bannister, Eva Sudbury, Paola Villanueva, Kirsten Perrett, Nigel Curtis

Pages 2736-2745

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 22 May 2021)

Open Access Article

[Hesitancy towards COVID-19 Vaccination among Healthcare Workers: A Multi-Centric Survey in France](#)

by Cécile Janssen et al and [on behalf of the ACV Alpin Study Group](#)

Vaccines 2021, 9(6), 547; <https://doi.org/10.3390/vaccines9060547> (registering DOI) - 22 May 2021

Abstract

Vaccination programs against COVID-19 are being scaled up. We aimed to assess the effects of vaccine characteristics on vaccine hesitancy among healthcare workers in a multi-center survey conducted within French healthcare facilities from 1 December 2020 to 26 March 2021. We invited any [...]

Open Access Article

[COVID-19 Vaccine Acceptability and Adherence to Preventive Measures in Somalia: Results of an Online Survey](#)

by [Mohammed A. M. Ahmed](#) et al

Vaccines 2021, 9(6), 543; <https://doi.org/10.3390/vaccines9060543> (registering DOI) - 21 May 2021

Abstract

Most countries are currently gravitating towards vaccination as mainstay strategy to quell COVID-19 transmission. Between December 2020 and January 2021, we conducted a follow-up online survey in Somalia to monitor adherence to COVID-19 preventive measures, and COVID-19 vaccine acceptability and reasons for vaccine [...]

Open Access Commentary

[COVID-19 Pandemic and Equal Access to Vaccines](#)

by [Matteo Bolcato](#) et al

Vaccines 2021, 9(6), 538; <https://doi.org/10.3390/vaccines9060538> (registering DOI) - 21 May 2021

Abstract

The COVID-19 pandemic has evidenced the chronic inequality that exists between populations and communities as regards global healthcare. Vaccination, an appropriate tool for the prevention of infection, should be guaranteed by means of proportionate interventions to defeat such inequality in populations and communities [...]

Open Access Article

[Knowledge, Attitudes and Perceptions of COVID-19 Vaccination among Healthcare Workers of an Inner-City Hospital in New York](#)

by [Federico Ciardi](#) et al

Vaccines 2021, 9(5), 516; <https://doi.org/10.3390/vaccines9050516> - 17 May 2021

Abstract

Introduction: New York City is one of the areas most affected by the COVID-19 pandemic in the United States. Healthcare workers are among those at high risk of contracting the virus, and a vital source of information and trust in vaccines to the [...]

Open Access Article

[Factors Affecting COVID-19 Vaccine Acceptance: An International Survey among Low- and Middle-Income Countries](#)

by [Suzanna Awang Bono](#) et al

Vaccines 2021, 9(5), 515; <https://doi.org/10.3390/vaccines9050515> - 17 May 2021

Abstract

Vaccination is fast becoming a key intervention against the ongoing COVID-19 pandemic. We conducted cross-sectional online surveys to investigate COVID-19 vaccine acceptance across nine Low- and Middle-Income Countries (LMICs; N = 10,183), assuming vaccine effectiveness at 90% and 95%. The prevalence of vaccine [...]

Value in Health

Volume 24 Issue 5 p605-752

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

*

*

*

*

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 22 May 2021

[No new, unique, relevant content]

BBC

<http://www.bbc.co.uk/>

Accessed 22 May 2021

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 22 May 2021

[No new, unique, relevant content]

Financial Times

<https://www.ft.com/>

Accessed 22 May 2021

[Gordon Brown: G7 must bear the burden of vaccinating the world](#)

May 21, 2021

Covid-19 vaccines

IMF says \$50bn is needed to end Covid pandemic in 2022

May 21, 2021

COVAX

Covax scrambles to make up vaccine shortfall due to Indian export halt

Serum Institute of India was due to provide more than a third of the scheme's forecast supply of doses for 2021

May 21, 2021

Forbes

<http://www.forbes.com/>

Accessed 22 May 2021

May 20, 2021

Over 75% Of Canadians May Need To Be Vaccinated Before Canada-U.S. Border Reopens

Over 75% of Canadians may need to be vaccinated before Canada-U.S. border can be opened.

By Sandra MacGregor Contributor

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 22 May 2021

Snapshot May 21, 2021

U.S. Global Health Leadership Must Go Beyond Command and Control

The United States neither can nor should abdicate a strong leadership role in global health. The question is how it leads.

Jonathan Cohen

Foreign Policy

<http://foreignpolicy.com/>

Accessed 22 May 2021

Latin America's Vaccine Stars and Struggles

Technology transfers to produce shots are slowly underway in the region.

By Catherine Osborn May 21, 2021

New Yorker

<http://www.newyorker.com/>

Accessed 22 May 2021

Medical Dispatch

The Struggle to Improve Vaccination Rates Among Latinos in New York

Vast disparities in immunization levels persist between the city's communities.

By [Stephania Taladrid](#) 6:00 A.M.

New York Times

<http://www.nytimes.com/>

Accessed 22 May 2021

U.S.

Vaccinations are lagging at many U.S. prisons, where major virus outbreaks have been common.

Only two in five federal inmates have gotten at least one shot so far, compared with three-fifths of adults nationwide. Despite the elevated risk behind bars, mistrust and refusal rates run high.

By Ann Hinga Klein and Maura Turcotte May 22, 2021

Asia Pacific

Pakistan's Private Vaccine Sales Highlight Rich-Poor Divide

An inoculation push, plagued with limited supplies and red tape, makes doses available to those who can pay for them. In a country with a struggling economy, most can't.

By Salman Masood May 22, 2021

Politics

100 Million Vaccine Doses Held Up Over Contamination Concerns, Firm Reveals

Executives from Emergent, which ruined millions of coronavirus vaccine doses, divulged to Congress the scope of the regulatory review of its troubled Baltimore plant.

By Sheryl Gay Stolberg and Sharon LaFraniere May 22, 2021

World

A vaccine maker in India signals it won't export doses before year's end, slowing aid to the world's poorest.

By Sameer Yasir May 19, 2021

The vaccination woes of some of the world's poorest nations will continue as the [Serum Institute of India](#), a crucial manufacturing pillar in the plan to supply two billion doses of Covid-19 vaccines to low-income countries, signaled that it would not be able to provide vaccines beyond India before the year's end.

The revelation, tucked into a statement by the vaccine manufacturing giant that attempted to deflect mounting criticism, was another setback for [Covax](#), the global vaccine partnership for the poor. It is already more than 140 million doses behind schedule, and the Serum Institute's announcement suggested it was all but impossible to meet the [goal of two billion doses](#) by the end of the year.

The announcement once again underscored the glaring contrast of inequality: As some of the richer nations tout levels of vaccinations that allow them to reopen their society, most of the poorer nations have barely gotten a start.

"We continue to scale up manufacturing and prioritize India," the Serum Institute of India said in the statement on Tuesday. "We also hope to start delivering to Covax and other countries by the end of this year."...

Washington Post

<https://www.washingtonpost.com/>

Accessed 22 May 2021

Biden says U.S. will provide coronavirus vaccines for 550,000 South Korean troops

In a joint news conference with South Korean President Moon Jae-in, President Biden pledged to provide vaccines for 550,000 South Korean soldiers who work with American forces. Biden and Moon also discussed a possible partnership on coronavirus vaccine manufacturing.

Politics · May 21, 2021

* * * *

Think Tanks et al

Brookings

<http://www.brookings.edu/>

Accessed 22 May 2021

[No new digest content]

Center for Global Development [to 22 May 2021]

<http://www.cgdev.org/page/press-center>

Content

Dear President Biden and Congress: Time for US to Lead Response to the Growing COVID-19 Global Vaccine Crisis

May 17, 2021

Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and safe vaccines, support rapid vaccine distribution and administration, and build a sustainable global network of vaccine manufacturing capacity. Vaccines offer an exit route out of the pandemic – but only if they reach a critical mass of people in need across continents, socioeconomic strata, and marginalized populations.

[Amanda Glassman](#), [Rachel Silverman](#) and [Prashant Yadav](#)

Chatham House [to 22 May 2021]

<https://www.chathamhouse.org/>

Accessed 22 May 2021

[No new digest content]

CSIS

<https://www.csis.org/>

Accessed 22 May 2021

Report

Open Letter Calling for Urgent High-Level US Leadership to Address Escalating Global COVID-19 Vaccine Crisis

May 17, 2021

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 22 May 2021

May 20, 2021 *News Release*

New Campaign from THE CONVERSATION / LA CONVERSACIÓN Responds to Information Needs about COVID-19 Vaccines Among Latinos and Spanish-speaking People in U.S.

News Release May 20, 2021 – THE CONVERSATION / LA CONVERSACIÓN expands to address information needs about the COVID-19 vaccines in the Latinx community with new videos featuring doctors, nurses and promotoras (community health workers) in English and Spanish. This installment of the campaign is produced by KFF (Kaiser Family...

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#))/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the [GE2P2 Global Foundation](#) – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *